

CURRICULUM VITAE

Pal Pacher M.D., Ph.D., F.A.P.S., F.A.H.A., F.A.C.C

Work Address: NIH/NIAAA/DICBR Laboratory of Cardiovascular Physiology and Tissue Injury,
5625 Fishers Lane, Room 2N-17
Bethesda, MD 20892-9413
Phone: (301)443-4830 Fax: (301)443-4830
Emails: pacher@mail.nih.gov ppacher@gmail.com ppacher@lycos.com
Web: <https://www.niaaa.nih.gov/about-niaaa/our-staff/pal-pacher-md-phd>
Google Scholar profile: <http://scholar.google.com/citations?user=XNRjTvcAAAAJ&hl=en>
Researchgatenet: http://www.researchgate.net/profile/Pal_Pacher Highly Cited 2014-2022: <http://highlycited.com/>
AD Scientific Index 2024: <https://www.adscientificindex.com/scientist/pal-pacher/4388725>

Education and Certifications:

INSTITUTION AND LOCATION	DEGREE	YEAR	FIELD OF STUDY
Semmelweis University of Medicine, Budapest, Hungary	M.D. (summa cum laude)	1993	Medicine
Hungarian Academy of Sciences, Budapest, Hungary	Ph.D. (summa cum laude)	2001	Cardiovascular Pharmacology

Professional Associations:

2011- American College of Cardiology (2011- Elected Fellow of ACC)
2007- Society for Leukocyte Biology
2006- The International Cannabinoid Research Society
2006- Society for Free Radical Biology and Medicine
2006- Nitric Oxide Society
2004- ASPET
2004- American Physiological Society (2006- elected Fellow of the Cardiovascular Section)
2001- American Heart Association (2006- elected Fellow of the Basic Cardiovascular Science Council)
2000-2006 Institute of Holistic Therapies, U.K.
1999-2002 Biophysical Society
1999- Juvenile Diabetes Association
2000- American Diabetes Association
1998-2001 New York Academy of Sciences
1997- International Society for Heart Research
1996- European Societies of Cardiology and Pharmacology

Honors and Awards:

2022- Included in Stanford University/Elsevier World's top 2% scientists list.
2021/2022 Highly Cited in Cross-Field category, Clarivate Analytics
2021 Intramural Scientific Research Achievement Award NIAAA/NIH
2019 Highly Cited in Pharmacology & Toxicology, Clarivate Analytics
2018-2019 President of International Cannabinoid Research Society; Organizer of 29th ICRS Symposium on Cannabinoids in Bethesda (over 500 participants)
2018 Highly Cited in Pharmacology & Toxicology, Clarivate Analytics
2017 Highly Cited 2017 in Pharmacology & Toxicology Included in: "The World's Most Influential Scientific Minds 2017", Clarivate Analytics
2016 Laboratory of Cardiovascular Physiology and Tissue Injury is the recipient of the NIH, Office of Research Services, Division of Occupational Health and Safety, *Laboratory Safety Award for Excellence*.
2016 Highly Cited 2016 in Pharmacology & Toxicology Included in: "The World's Most Influential Scientific Minds 2016", Thomson Reuters
2015 Highly Cited 2015 in Pharmacology & Toxicology (based on number of total citations of highly cited papers during past 11 years <http://highlycited.com/>) Included in: "The World's Most Influential Scientific Minds 2015", Thomson Reuters
2015 November, Honorary Doctorate (Doctor Honoris Causa) from Medical Faculty of Semmelweis University, Budapest
2014 Highly Cited 2014 in Pharmacology & Toxicology (based on number of highly cited papers during past 10 years <http://highlycited.com/>) Included in: "The World's Most Influential Scientific Minds 2014", Thomson Reuters
2012- "Star reviewer" selected by the Editor of AJP Heart Circulatory Physiology (announced FASEB Meeting, 2012)

- 2012- Award and Plenary Lecture of the *International Cannabinoid Research Society* Board of Directors presented at the 2012 ICRS Annual Symposium in Freiburg, Germany
- 2012- Elected Honorary Member of the Hungarian Society for Experimental and Clinical Pharmacology
- 2012 May- Listed in top 50 most cited in the World in Pharmacology and Toxicology field during the past decade based on total citations in the field (Institute of Scientific Information/ISI)
- 2010- Listed in the top 100 most cited in the World in Pharmacology and Toxicology field during the past decade (ISI)
- 2010- Listed in top 1% cited in Clinical Medicine, Biology and Biochemistry fields during the past decade (ISI)
- 2011 June- Elected Fellow of the American College of Cardiology
- 2011 - "Star reviewer" selected by the Editor of *AJP Cell Physiology* (announced FASEB Meeting, 2011)
- 2011 Jan- Adjunct Professor, University of Texas Medical Branch, Department of Anesthesiology
- 2011- Steering Committee Member of the Cancer Redox Biology Faculty, National Cancer Institute (NCI)
- 2008 - Sanofi Aventis Award
- 2007- Thomson ISI, fast breaking paper in the field of pharmacology: **P Pacher, S Batkai, G Kunos.** The endocannabinoid system as an emerging target for pharmacotherapy. *Pharmacological Reviews* **2006; Sept; 58(3): 389-462. (Cited over 2650 times (Google scholar), #5 top cited paper in Pharmacology field 2006-2009, Scopus). Hottest paper in *Pharmacological Reviews* of all times (1078 Altmetrics score).**
- 2007 - ISI: hot paper in Biochemistry; most highly cited in *Physiological Reviews* since 2007: **P Pacher, JS Beckman, L Liaudet.** Nitric oxide and peroxynitrite in health and disease. *Physiol Reviews* **2007; Jan; 87(1):315-424** (cited over 7600 times (Google scholar); #2 top cited paper in Biology/Biochemistry, Essential Science Indicators, Thomson 2009; Editors' selection for hottest paper in *Physiological Reviews* 2008, 2009, 2010, 2011); among the top 5 most highly cited papers in *Physiological Reviews* of all times.
- 2006/2007 - 4 Publication Awards, NIH/NIAAA
- 2006- Elected Fellow of American Heart Association
- 2006 - Elected Fellow of American Physiological Society Cardiovascular Section
- 2004 - Best Poster Award, International Society for Heart Research, Brisbane, Australia
- 2004- Award of Nitric Oxide Society, Nara, Japan
- 2004- Award for Research Excellence, National Institutes of Health, Bethesda, USA
- 2000-2001 Postdoctoral Fellowship Award of Juvenile Diabetes Association
- 1999- Sigma-Aldrich Research Award
- 1999- Award of Hungarian Pharmacological Society on Young Researcher Competition
- Scientific Research Award of TEVA-Biogal Pharmaceutical Company for the best drug-developmental proposal in the CNS, Budapest, Hungary
- 1998- Young Investigator Award of International Society for the Study of Hypertension in Pregnancy (ISSHP), Kobe, Japan
- 1997- Award of Hungarian Pharmacological Society on Young Researcher Competition.
- Travel Awards: 1997-1999: Travel Award of ISSHP; Travel Award of Soros Foundation; Travel Award of Hungarian Society of Cardiology; Travel Award of Semmelweis University of Medicine.
- Consultancy/scientific advisory board (before NIH): Pfizer, Merck, P&G, Millar Instruments

Scientometrics: over 380 publications

Total citations: over 65,000 (over 20,000 since 2020); Hirsch H index: 133 (Google Scholar); Egghe's G-index: 244.

According to total citations (ISI, past 10 years) ranked in top 50-10 in Pharmacology field in the World and in top 1% in Clinical Medicine, Biology and Biochemistry fields.

Included in the list of Highly Cited Researchers 2014, 2015, 2016, 2017, 2018, 2019, 2021, 2022 in Pharmacology & Toxicology or Multiple fields (<http://highlycited.com/>) based on the number of highly cited papers and total citations during 2002- 2014/2015/2016. and in: "The World's Most Influential Scientific Minds 2014, 2015, 2016 and 2017-2019", Institute of Scientific Information, Thomson Reuters/Clarity Analytics.

Research interest:

Cardiovascular physiology and pharmacology, alcohol use disorder, aging, diabetes, and diabetic complications, oxidative/nitrosative stress and inflammation, lipid endocannabinoid signaling system. Identification of novel therapeutic targets and diagnostic tools against cardiovascular and other disorders associated with oxidative stress, inflammation, and tissue injury, including those triggered by excessive alcohol consumption. Complex hemodynamic measurements.

Professional Work Experience:

- 2015- Head, Laboratory of Cardiovascular Physiology and Tissue Injury, NIH/NIAAA
- 2012- Tenured Senior Investigator, National Institutes of Health/NIAAA
- 2012- Scientific Advisor (unpaid), Dept. Pharmacology, Semmelweis University, Hungary
- 2011- Adjunct Professor, University of Texas Medical Branch, Department of Anesthesiology
- 2005- Section Chief, Oxidative Stress and Tissue Injury, Laboratory of Physiologic Studies, NIAAA/NIH

Pal Pacher M.D., Ph.D. - CV

2003-2004 Senior Research Fellow, Laboratory of Physiologic Studies, NIAAA, NIH, Bethesda, USA
2001-2002 Senior Cardiovascular Pharmacologist (Principal Investigator in 8 NIH grants (\$1.86 million),
co-investigator in 6 grants (\$1.65 million), Inotek Pharmaceuticals, Beverly, USA
1999-2001 Visiting Research Scientist, Dept. of Pathology and Cell Biology, Thomas Jefferson Medical University,
Philadelphia, USA
1996-1999 Ph.D. student in First National Institute of Cardiology and Dept. of Pharmacology, Semmelweis Univ of Med.,
Budapest, Hungary
1995-1999 Assistant Professor of Pharmacology, Dept. of Pharmacology, Semmelweis University of Medicine
1994 Lecturer of Pharmacology, Dept. of Pharmacology, Semmelweis University of Medicine, Budapest, Hungary

Editorial Boards:

Regional Editor (U.S.A.): 2003-2017 Current Vascular Pharmacology
2007-2013 Cardiovascular & Hematological Agents in Medicinal Chemistry

Associate Editor: 2010- The Journals of Gerontology, Series A: Biological Sciences
2016- Geroscience, The Official Journal of the American Aging Association

Editorial Academy: 2006- International Journal of Molecular Medicine

Editorial Board: 2007- Frontiers in Bioscience
2006-2014 Current Medicinal Chemistry
2005-2014 Current Drug Targets Cardiovascular & Hematological Disorders
2010- Diabetes Review Letters
2010-2019 World Journal of Gastroenterology
2010- Alcohol
2011-2020 Free Radical Biology and Medicine
2011- American Journal of Physiol Heart and Circulatory Physiology
2012- American Journal of Physiol Cell Physiology
2015- Scientific Reports (Nature)
2019- British Journal of Pharmacology

Editor: special issues:

2005- Current Vascular Pharmacology, Hot Topic Issue: Role of Oxidative-Nitrostatic Stress and Poly(ADP-ribose) Polymerase in Cardiovascular Pathophysiology
2008-2009: Frontiers in Bioscience: Nitric oxide, superoxide and peroxynitrite in cardiovascular diseases (with Prof. Ferid Murad, co-winner of the 1998 Nobel Prize in Physiology/Medicine)

Teaching:

1991-1993 Assistant Lecturer of Pharmacology and Microbiology
Jan 1994- July 1994 Lecturer of Pharmacology, Dept of Pharmacology, Semmelweis University of Medicine, Budapest,
Hungary
Aug 1995-Febr 1999 Assistant Professor of Pharmacology, Dept of Pharmacology, Semmelweis University of Medicine

My responsibility was teaching Pharmacology and Toxicology (32 hours/week) for Medical Students, Students of Dentistry and Pharmacy. I also participated in the PhD training program of the Department in cardiovascular physiology and pharmacology.

Students/researchers supervised (with current degree/s and position):

Zoltan Ungvari M.D., Ph.D.	1997-1999	(Tenured Professor, Donald W. Reynolds Chair of Aging Research, Univ. of Oklahoma Health Sciences Center, USA)
Lako-Futo Zoltan M.D.	1996-1998	(Physician, 1 st Intern Med Hospital, Budapest, Hungary)
Zsolt Bagi M.D., Ph.D.	1997-1999	(Professor, Univ of Georgia, USA)
Gabor Szalai M.D.	1995-1998	(Cardiologist, Baylor College, Texas, USA)
Katalin Komjati M.D., Ph.D	2000-2002	(Research Scientist, Inotek Pharmaceuticals)
Peter Bai, PhD	2000-2003	(Professor Univ of Debrecen)
Rita Benko Ph.D.	2002-2003	(Assistant Professor, Inst. of Human Physiol, Budapest, Hungary)
Anne Vaslin	2002-2003	PhD Student, Lausanne, Switzerland)
Lucas Liaudet M.D.	2001-2002	(Professor, Dept. of Internal Medicine, Lausanne, Switzerland)
Cziraki A M.D, Ph.D.	2001-2003	(Professor, Vice Dept. Head, Heart Institute, Pecs University, Hungary)
Xiao CY M.D.	2002-2003	(Research Scientists, Inotek Pharmaceuticals, Beverly, USA)
Chen M M.D.	2002-2003	(Research Scientists, Inotek Pharmaceuticals, Beverly, USA)
Sharon Zac	2002	(Animal Technician, Inotek Pharmaceuticals, Beverly, USA)
Long-Sheng Lu, M.D.	2003	(Research Fellow, Graduate Institute of Pharmacology, National Taiwan University)

Pal Pacher M.D., Ph.D. - CV

Zsusanna Zsengeller M.D., Ph.D	2002-2003	(Assistant Professor of Medicine, Harvard Medical School, Boston)
Oleg V. Evgenov M.D., Ph.D.	2003-2004	(Anesthesiologist, Harvard Medical School, Boston)
Lucja Flis	2005	Special volunteer, (college student)
Nora Czifra	2006	Special volunteer, (Proposal Specialist at EarthBalance)
Anjum Jafri	2005- 2006	Research technician
Partha Mukhopadhyay Ph.D.	2006-	Research Fellow (Staff Scientist 2009-)
Mohanraj Rajesh Ph.D.	2006-2011	Research Fellow, (Assistant Professor in UAE) (FARE Award winner 2009; since 2009-2011 supported by Sanofi Aventis Fellow Award)
Vivek Patel	2007-2010	Special volunteer/high school summer student, (now college student)
Lauren Becker	2008	Special volunteer/ high school summer student, (now college student)
Rachel Gao	2009-2010	Special volunteer/ summer student, (now Senior Scientist at InDevR, Inc.)
Galim Tanchian	2010-2011	Special volunteer/ high school summer student, (now Pharmacist)
Malek Kechrid	2010-2011	Special volunteer/ summer student, (Fellow at NCI/NIH)
Bela Horvath MD., Ph.D.	2010-2011	Supplemental Research Fellow, supported by Hungarian National Innovation Office (FARE Award winner 2011; among top 21 selected to present at NIH Research Festival by the Chair) (now Pathologist at Cleveland Clinic)
Sandor Batkai MD., Ph.D.	2010-2010	Staff Scientist, (now group leader at Institute of Molecular and Translational Therapeutic Strategies, Hannover, Germany)
Enrique Guerrero-Beltrán	2010	Special volunteer, guest researcher for 3 mo, supported by Universidad Nacional Autónoma de México (Received PhD in part based on the work done at NIH in 2011; now Professor, University of Monterrey)
Zongxian Cao MD., Ph.D.	2011-2014	IRTA Fellows (now Pathologist at Hackensack Pathology Associates, Llc)
Enkui Hao MD	2011-2012	Guest researcher, supported by fellowship from China (Cardiologist)
Wen-Shin Lee MD	2011-2012	Guest researcher, supported by fellowship from Taiwan; (now Interventional Cardiologist in Taiwan)
Eileen Holovac	2011-2014	Special volunteer/high school summer student (Pharmacist, Rockville)
Katalin Erdelyi Ph.D.	2012-2015	Vis. Res. Fellow (Biologist at National Institute of Oncology)
Yuping Wang Ph.D.	2012-2013	Guest Researcher, supported by fellowship from China, now PI, Associate Professor
Lisheng Jiang M.D.	2013-2014	Guest Researcher, supported by fellowship from China, now Cardiologist
Sevil Aliyeva M.D.	2014-2014	Special volunteer (Endocrinologist)
Csaba Matyas M.D.	2015-2016	Guest Researcher (now Radiologist at University of Pecs)
Zoltan Varga M.D., Ph.D.	2015-2019	Vis. Res. Fellow; (Recently: Vice Chair Dept. of Pharmacol., Ssemelweis Benedict J. Latteri Award for Excellence in Scientific Publication NIAAA
Mike Nan	2015-2016	Post-Bac IRTA Fellow (Recently: Univ. Of Maryland student)
Balazs Nemeth MD	2016- 2017	Guest Researcher (Heart and Vasc Center Ssemelweis Univ. Cardiologist)
Cody Savage	2018-2019	College student (Recently Student in Univ of Alabama)
Suxian Zhao MD	2018-2020	Guest Researcher/Special Volunteer (Recently Pathologist in China)
Janos Paloczi Ph.D.	2015-	Res.Fellow; FARE Award; K99 Award in 2020 (Assistant Prof. at LSU)
Csaba Matyas MD, PhD	2018-2020	Visiting Research Fellow (Guest Researcher 2015-2016) Benedict J. Latteri Award for Excellence in Scientific Publication NIAAA Daniel W. Hommer Award for Outstanding Fellow, NIAAA/NIH
Eszter Trojnar MD, PhD	2018-	Supplemental guest research; from 2019 Visiting Research Fellow 2021 Daniel W. Hommer Award for Outstanding Fellow, NIAAA/NIH
Arif Muhammad PhD	2022-	Visiting Research Fellow (mentoring award)
Chao Quan PhD	2023-	Visiting Research Fellow
Bruno Paes Leme Ferreira DVM	2022-	Visiting Research Fellow
Estifanos Yohannes Getiye PhD	2022-	Visiting Research Fellow
Burhan Yokus MD	2023-	Special Volunteer and Visiting Research Fellow
Lihong Fu PhD Student	2024-	Special Volunteer

Grant review/study sections, committees, etc.:

National/International:

Philips Morris USA: grant reviewer: 2005-2007

Wolfermann-Nägeli Foundation, Germany: grant reviewer: 2008

Catalan Agency for Health Technology Assessment and Research, Spain: grant reviewer:

2008 Hungarian Research Council: grant reviewer: 2008, 2009

Trinity College Dublin: External reviewer for Senior promotions committee: 2008, 2009

University of Tromso, Norway: External reviewer/1st opponent for PhD defence 2007 (Dr. Elena Egorina)

University of Calgary in Calgary, Alberta, Canada: External reviewer for PhD defence 2008 (Dr. Ali

Pal Pacher M.D., Ph.D. - CV

Gaskari) Alberta Heritage Foundation, Canada: grant reviewer: 2007, 2008, 2009, 2010
American Diabetes Association: ad hoc reviewer; American Heart Association: ad hoc reviewer, abstract review
The Wellcome Trust: grant reviewer: 2009, 2010; Cancer Research UK: grant reviewer: 2009
Health Research Board, Ireland, grant review: 2011;
French National Research Agency "Blanc SVSE 2":
2010
Juvenile Diabetes Research Foundation International: Targets of ROS in T1D complications study section: 2010
Society for Free Radical Biology and Med: abstract reviewer:2008-2011;2020; 2022, 2023 Young Investigator Award
Committee:2009
Society for Free Radical Biology and Medicine: Discovery Award Committee: 2011
Member of the Scientific Organizing Committee The International Cannabinoid Research Society Annual Meetings 2008, 2009,
2010, 2016, 2018, 2019, 2020, 2021, 2022, 2023
Society for Free Radical Biology and Medicine: Senior Life Achievement Award Committee: 2010, 2012, 2013, 2014,
2015, 2016, 2017, 2019, 2020, 2021, 2022, 2023
Program Committee for Society for Free Radical Biology and Medicine's 19th Annual Meeting to be held in San Diego, CA,
November 14 - 18, 2012 (SFRBM 2012)
Alzheimer Foundation: grant reviewer: 2011
Medical Research Council, UK: grant reviewer: 2008, 2009, 2010, 2011
Romanian Council for Research and development: grant review: 2012
National Science Center, Poland: grant review: 2012
Swiss National Fund for Scientific Research: grant reviewer: 2007-2011, 2012, 2022, 2024
Israel Science Foundation: grant review: 2012, 2022, 2023
ADA diabetes/diabetic complications study section member 2015-2017
Hungarian Academy of Sciences: grant reviewer "Momentum 2012"
Hungarian Research Council: special consortium executive grant review committee"Nagyosszegu OTKA": 2008, 2009,
2012, 2013, 2014
2015 MRMCM-BAA CCC review panel (DOD)

NIH:

Institutional ACUC committee:2005-
2006- Regular FARE judge, NIH:
NIH Research festival: abstract reviewer: 2009, 2010, 2011
National Cancer Institute: SBIR Contract Proposals for NCI's Topic 255 "Development of Anti-cancer Agents' study
section: 2009
NIH Intramural Research Program"Earl Stadtman Investigators" search committee Member: Pharmacology/Molecular
Targets/Molecular Pharmacology/Cell Signaling: 2009-2010; 2022
NIH Intramural Research Program"Earl Stadtman Investigators" search committee Member: Physiology: 2010-2011;
NIH/NIDDK: PAR-08-181 Seeding Collaborative Interdisciplinary Team Science in Diabetes, Endocrinology and
Metabolic Diseases (R24) study section: 2011Oct
Steering Committee of the Cancer Redox Biology Faculty, National Cancer Institute: 2011-
Intramural Loan Repayment Programs (ILRP) Scientific Review Committee: 2014, 2016,
2018, 2019, 2020, 2021, 2022, 2023, 2024
NIH Intramural Research Program"Earl Stadtman Investigators" search committee Member: Pharmacology: 2012, 2013,
2014, 2015 and 2016, 2022
NIH, Panel: Synthetic Psychoactive Drugs and Strategic Approaches to Counteract their Deleterious Effects, Division of
Neuroscience, Development and Aging (DNDA) Center for Scientific Review, NIH 2017
NIH DDIR Innovation Award program review 2017
NIH Director's representative on BSC presentation of an NIA Investigator 2019

Reviewer:

Circulation; Circulation Research; The Journal of Clinical Investigation; J Am Coll Cardiol; Hypertension;
Arteriosclerosis Thrombosis and Vascular Biology; Cardiovasc Res; J Mol Cell Cardiol; Diabetes; Diabetes Care;
Diabetologia; Diabetes/Metabolism Research and Reviews; Am J Pathology; Am J Physiology (AJP) Heart Circulation
Physiology; AJP Cell Physiology; AJP Lung Cellular and Molecular Physiology; AJP Endocrinology and Metabolism;
AJP Regulatory, Integrative and Comparative Physiology; AJP Gastrointestinal and Liver Physiology; Acta Physiologica
Scandinavica; FASEB J; J Physiology London; Journal of Pharmacology and Experimental Therapeutics; British Journal
of Pharmacology; Biochemical Pharmacology; Toxicology; Toxicology Letters, Molecular Pharmacology; Current
Vascular Pharmacology; J Cardiovascular Pharmacology; Methods and Findings in Experimental and Clinical
Pharmacology; Can J Pharmacol Physiol; International Journal of Molecular Medicine; Current Medicinal Chemistry;
Current Drug Targets Cardiovascular & Hematological Disorders; Cardiovascular & Hematological Agents in Medicinal
Chemistry; Journal of Pharmacology and Toxicology; Critical Care Medicine; Critical Care; Am J Respir Crit Care Med;
Shock; Life Sciences; J Neurochemistry; International Journal of Cancer; Oncology Reports; European Journal of
Cancer; Brain Research; Kidney International; Transplant International; Free Radicals Biol Med; Expert Opinions on
Therapeutic Patents; Recent Patents on Inflammation & Allergy Drug Discovery; Journal of Cardiac Failure; Alcohol;
American Journal of Psychiatry; Molecular and Cellular Biology; Cardiovascular Drug Reviews; Experimental Biology

Pal Pacher M.D., Ph.D. - CV

and Medicine; Gastroenterology; Hepatology, J Hepatology, Journal of Clinical Anesthesia; Journal of Neurophysiology; Cardiovascular Drugs and Therapy; Experimental and Clinical Endocrinology&Diabetes; Neurochemistry; J Molec Endocrinology; Antimicrobial Agents and Chemotherapy; Journal of Molecular Medicine; Endocrinology; Immunobiology; Journal of Diabetes and its Complications; Journal of Interventional Cardiac Electrophysiology; FEBS letters; Experimental Gerontol; Mech. Ageing Dev.; Aging Cell; Rejuvenation Research; Gerontology; Nature Medicine; Nature Reviews Endocrinology; Chemical Reviews; Pharmacological Review; Nature Chemical Biology; Nature Reviews Drug Discovery; Nature Communications, Nature Reviews Cardiology, TIPS; PNAS USA; Scientific Report

Grants and Contracts:

Present: NIH/NIAAA Intramural program (since 2003)

- Since 2003-: Research is supported by the Intramural Research Program of the NIH; unpaid consultant in various NIH, AHA, ADA and international grants (can be only unpaid consultant in "outside grants" because of the NIH and/or other agencies' regulations)
- 2008-2010: Receptient of Sanofi Aventis Fellow Award Grant (to support Dr. Mohanraj Rajesh's training: app. 70,000/year for 2 years)
- 2010-2011: Fellowship Award from Hungarian Research Council (to support Dr. Bela Horvath's stay at NIH: app. 60,000/year for 2 years)
- 2011: University funds from Taiwan and China to support 2 cardiologist's research training at NIH/NIAAA for 1 year
- 2012-2017: 1 U01 AA021122-01 Collaborative Extramural-Intramural Grant: "Cell Death in Alcoholic Heart and Muscle" Extramural PIs: Hajnoczky Gyorgy (contact), Rubin Emanuel; Intramural: Pal Pacher (total \$348,750/year for 5 years). No resources are provided for the Intramural PI.
- 2012-2013 Chinese Research Fellowship for training of:
Dr. Yuping Wang
Dr. Lisheng Jiang
- 2015-2018: Foundation awards to support training of Postdoctoral Fellows at NIH (from Semmelweis MedicalUniversity and American Hungarian Science Foundation) to:
Drs. Zoltan Varga
Dr. Csaba Matyas
Dr. Balazs Nemeth
Dr. Eszter Trojnar
- 2016-2021: 1U01AA023552-01A1 Collaborative Extramural-Intramural Grant: Novel CB2 agonists shield brain from HIV infection and alcohol exposure. Extramural PI: Yuri Persidsky; Intramural: Pal Pacher (total 1.755 million /5 years). No resources are provided for the Intramural PI.
- 2017-2022: 1U01AA024733-01A1 Autophagy in Alcoholic Pancreatitis PI. Extramural P.I.: Wen-Xing, Ding; Intramural: P.P

Past (before NIH (2003))

Principal Investigator

No.	Title	Period of Performance	Total Grant
1 R43 GM63274-01A1	Novel xanthine oxidase inhibitor for hemorrhagic shock	8/1/01-8/31/02	\$214,161
1 R43 GM64016-01A1	Peroxynitrite decomposition catalyst for hemorrhagic shock	5/1/02-4/30/03	\$235,780
1 R43 HL69419-01	PARS inhibitor for cardiac allotransplantation	5/1/02-4/30/03	\$197,929
1R43CA95807-01	Poly (ADP-ribose) polymerase and doxorubicin cardiotoxicity	7/1/02-6/30/03	\$250,000
1R43GM63274-01A2	Peroxynitrite decomposition catalyst for hemorrhagic shock	2/01/02-1/31/03	\$177,375
1R43HL69548-01A1	Peroxynitrite decomposition catalysts for bronchiolitis obliterans Chronic heart failure: the role of poly (ADP-ribose)	7/1/02-6/30/03	\$150,224
1R43HL71381-01	polymerase activation	9/2/02-8/30/03	\$315,259
1R43HL071381-01A1	Chronic heart failure and PARP inhibition	12/1/02-12/1/03	\$315,259
			1,855,987

Co-Investigator

No.	Title	Period of Performance	Total Grant
1 R43 HL68298-01	PARS inhibitor therapy of smoke inhalation injury	8/1/1-1/31/03*	\$270,590
1R43CA86149-01A1	A nitric oxide synthase inhibitor for intestinal polyposis	9/1/01-9/29/03	\$850,853
1 R43 HD41288-01	Novel therapy for female sexual dysfunction	9/15/01-9/13/02*	\$229,792
1R03AG21206-01	Reactive nitrogen species and cardiovascular aging	7/1/02-6/30/03	\$79,502
1R43HL70342-01	Xanthine oxidase inhibitor for congestive heart failure Doxorubicin cardiotoxicity:protection by peroxynitrite	7/1/02-12/31/02	\$220,870
1R43CA097559-01	decomposition catalyst		1,651,607

Presentations: (selected)

- 2023 Yale Conference for Alcohol Research & Education (YCARE), Yale University School of Medicine, New Haven, CT: Invited Speaker “Alcohol and cardiovascular function and injury”
- 2023 Alcohol Gordon Conference 2023, Ventura, CA: Speaker “The effect of chronic moderate and heavy alcohol consumption on cardiovascular aging”
- 2023 Cannabinoid Function in CNS Gordon Conference, Spain: Speaker “CB2R detection in the brain gets a second look.”
- 2023 Pharma R&D: Plenary Speaker: “Targeting cannabinoid 2 receptors (CB2R) for therapeutic gain: promises and difficulties.”
- 2023 7th International Conference on Drug Discovery & Lead Optimization 2023, San Francisco, CA: Keynote Speaker: “Targeting cannabinoid 2 receptors for inflammatory diseases: pitfalls and opportunities.
- 2023 NIAAA Council meeting, Bethesda, MD, Speaker “Understanding the interplay of oxidative stress, inflammation, cell death and lipid signaling in tissue injury and AUD-related pathologies; identification of new therapeutic targets.”
- 2023 NHLI/NIH Symposium on “Cannabis and Cannabinoids in Heart, Lung, Blood, and Sleep” speaker “Pharmacology of endocannabinoids, marijuana derived phytocannabinoids (THC and cannabidiol) and other constituents of marijuana (e.g. terpenes, flavonoids, etc), and synthetic cannabinoids with focus on cardiovascular impact: the good, the bad, and the ugly”
- Pharma R&D 2022, Plenary Speaker
- 2022 ICRS 2022, Galway
- 2022 New York Medical College 2022
- 2022 Annual meeting of WHMA, Florida
- 2022 Nov American Heart Association Annual Meeting Chicago
- FOCIS 2020: Laval University Quebec and Meeting of Canadian Society for Immunology
- 2019 Nov, Invited Speaker, Semmelweis Symposium, Budapest Hungary
- 2019 June 29-July 04, President, Scientific Organizer, 29th Annual ICRS Symposium on Cannabinoids Bethesda (over 500 participants)
- 2019 Invited Speaker, Laval University, Quebec City, Canada
- 2019 Invited Speaker, Skaggs School of Pharmacy and Pharmaceutical Sciences, Univ. of Colorado
- 2019 March, Invited speaker: Alcohol Gordon Conference
- 2018 July; ICRS, Leiden, Session Chair, Organizing Committee and Board of Directors Member
- 2018 May; Keynote speaker on 2nd International Pressure-Volume User Group Meeting, Paris, France
- 2018 April; Invited speaker on Frontiers in CardioVascular Biology 2018, Vienna, Austria
Chair session: New strategies for cardioprotection to prevent heart failure.
- 2017, June 22-27; program committee of ICRS20017, Montreal; Chair session on “Feeding, metabolism and obesity.”
- 2017, June 4-6; invited keynote speaker and session chair at The 2nd International Medical Cannabis Conference June 4-6, 2017 Tel Aviv, Israel
- 2017, June: Invited speaker at Hebrew University Cannabinoid Research Center, Jerusalem, Israel
- 2017, April: invited keynote speaker at 23rd Scientific Conference of the Society on NeuroImmune Pharmacology (SNIP), Philadelphia
- 2016, June; ICRS Annual Symposium in Bukovina, Poland; Speaker/Chair Metabolism
- 2016, June; Invited Speaker, 39th Annual Conference on Shock, Austin, Texas; “The endocannabinoid system in shock”.
- 2016, April 2-6; Invited Speaker, ASPET Annual Meeting at Experimental Biology 2016, in San Diego, CA, April 2-6, 2016, Symposium on “Novel Targets for Treatment of Cardiometabolic Diseases” “Interplay of oxidative stress, inflammation and the endocannabinoid system in diabetic cardiomyopathy”.
- 2016, March 22-23, Invited seminar Dept of Pharmacology, Toxicology and Therapeutics, KU Medical Center. “Modulation of cannabinoid 2 receptors (CB2): successes and difficulties?”
- 2016, January 18, Invited Speaker Temple University, Center for Substance Abuse Research at the Department of Pathology Temple University School of Medicine PA.” Where are we going with modulation of CB2 receptors: successes and difficulties?”
- 2015, Nov 10-13, Invited Seminars, Semmelweis Medical University, Dept of Pharmacology, Hungarian Institute of Cardiology, Department of Interventional Cardiology, Budapest. (recipient of honorary degree)

Pal Pacher M.D., Ph.D. - CV

- 2015, October, Invited Speaker, 2nd Swiss Endocannabinoid Pharmacology Meeting, University of Bern, Switzerland, Cannabinoid 2 receptors in fibrotic diseases: quo vadis?
- 2015, October, Invited Seminar, Department of Intensive Care Medicine, University Hospital and Faculty of Biology and Medicine, Lausanne, Switzerland
- 2015, May, Invited Seminar, Mitocare Center, Thomas Jefferson, PA
- 2015, March 4-7, Medical Cannabis and Cannabinoids: policy, science and medical practice, Prague; plenary speaker
- 2014, Sept 24-26, 8th International Symposium on Cell/Tissue Injury and Cytoprotection/ organoprotection. Budapest, Hungary, “Role of the endocannabinoid system in cardiovascular injury and inflammation”
- 2014, July 14th, NIDA, Bethesda, “Targeting cannabinoid receptor 2 (CB2) in inflammation and tissue injury for therapeutic gain: successes and difficulties.”
- 2014, July 3rd, GW Pharma External Collaborator Advisory Meeting, Chair Neurology and Psychiatry
- 2014, July 2nd, ICRS, Baveno, Italy, “Peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephropathy”; “Protective effect of the phytocannabinoid betacaryophyllene in liver ischemia-reperfusion injury.”
- 2014, June 23-27, International Conference on the Bioscience of Lipids, University of Aberdeen, Scotland, “Endocannabinoid system in diabetes and diabetic complications”
- 2014, June 21, 37th Annual RSA Scientific Meeting and 17th Congress of ISBRASeattle, “Role of poly(ADP)ribose polymerase in regulation of cell fate, inflammation and metabolism in liver disease”
- 2014, April 24, Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada,
- 2014, Jan 27, Food and Drug Administration, Bethesda, “Targeting the endocannabinoid system in inflammation and tissue injury for therapeutic gain.”
- 2013, SFRBM 2013, San Antonio, “Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis.”
- 2013, June 22-26, 36th Annual RSA Meeting, Orlando, Florida, “The effect of moderate and heavy alcohol consumption on cardiovascular aging”
- 2013, Dec, LSU, New Orleans, “Modulation of the endocannabinoid system in tissue injury: promises and challenges”
- 2013, 49th EASD Annual Meeting, Barcelona, Spain, “The endocannabinoid system in diabetic complications”
- 2012, Oct 09, Signal transduction and redox physiology NCI/NIH
- 2012, Sept 6-7; The 7th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C), China
- 2012, July 22-27, Plenary Lecture of International Cannabinoid Research Society (ICRS) Board of Directors at the ICRS Annual Symposium in Freiburg, Germany
- 2012, Sept 19-21, Plenary Honorary Lecture at 50th anniversary meeting of the Hungarian Society for Experimental and Clinical Pharmacology, Budapest, Hungary
- 2012, AHA, Annual Meeting
- 2011, Dec, 50th Anniversary Meeting of Phytochemical Society of North America; Hawaii, Medicinal Plants:” Nonpsychoactive constituents from Cannabis sativa (marijuana):Therapeutic potential in inflammatory disorders and diabetes”
- 2011, June, RSA meeting “Role of poly(ADP-ribose) polymerase (PARP) in liver injury, inflammation and fibrosis”
- 2011, May, 102 AOCs Annual Meeting, Cincinnati, “Opposing Effects of Cannabinoid-1 and 2-receptors on Inflammation and Oxidative Stress: Implications for Tissue Injury.”
- 2010, November, Redox Biology in Immunology and Cancer Workshop, National Cancer Institute, Bethesda, Maryland: “The role of the endocannabinoid system in inflammation, oxidative stress, and cell death: implications for tissue protection/injury.”
- 2010, October, Joint Research Conference of the Institute for Advanced Studies the Hebrew University and the Israel Science Foundation on: CANNABINOIDS IN BIOLOGY AND MEDICINE, Jerusalem, Israel:

Pal Pacher M.D., Ph.D. - CV

- “Role of the CB₂ receptors in inflammation and tissue injury: interplay of activated endothelium and inflammatory cells”
- 2010, October, Redox Biology course, National Cancer Institute, Bethesda, Maryland: “Endocannabinoids and plant-derived cannabinoids in inflammation, redox regulation and cell death: implications for tissue protection or injury”.
 - 2010, September, The 2010 ISBRA World Congress, Paris, France: Symposium Organizer on the Role of ROS/RNS in liver injury; Session Chair: Molecular mechanisms of alcoholic liver disease: Roles of endocytosis, PARP, TGF- β
 - 2010, August, Federation of the Societies of Biochemistry and Molecular Biology course on Free Radicals, invited speaker: “Methods for the detection of ROS by flow cytometry and imaging” and “ROS/RNS and diseases: animal models.”
 - 2010, July, The International Cannabinoid Research Society Annual meeting, Lund, Sweden: Session Chair: Metabolism and feeding behavior” Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy ”Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and –independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells and cardiomyocytes”
 - 2010 June, University of Bonn, Germany, Workshop for the DFG Research Unit 926: The Endocannabinoid System: “From Physiology to Pathophysiology”, Session Chair: Inflammation and Aging ‘Interplay of oxidative/nitrosative stress, inflammation, cell death signaling pathways and the endocannabinoid system: Implications for cardiovascular disease.”
 - 2010 June, University of Hannover, Germany, “Role of cannabinoid-2 receptors in inflammation and tissue injury”
 - 2010 May, Budapest, Hungarian Academy of Sciences
 - Department of Pathology and Laboratory Medicine, 2010 Temple University School of Medicine “Anti-inflammatory and antioxidant effects of CB₂ activation in endothelial cell biology and end-organ protection”
 - LSUHSC, Dept of Pharmacology, 2010 Febr, The interplay of the oxidative/nitrosative stress and the endocannabinoid system in cardiovascular disease and tissue injury
 - NIH, Pain Interest Group, 2010 “Interplay of the endocannabinoid system with oxidative-nitrosative stress and inflammation in models of tissue injury’
 - American Heart Association, Scientific Sessions, 2009, Nov “Cannabidiol Attenuates Myocardial Dysfunction, Fibrosis, Inflammation, Cell Death and Interrelated Signaling Pathways Associated With Diabetic Cardiomyopathy”
 - Experimental Biology Meeting, New Orleans 2009 Apr “Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation and cell death”
 - Dept. of Physiology, Louisiana State University Health Sciences Center 2009 Apr “Role of oxidative/nitrosative stress and poly(ADP)-ribose polymerase in cardiomyopathy and heart failure”
 - University of Calgary, Canada 2009 Apr “Role of the endocannabinoid system in cardiovascular disease”
 - The Hungarian Scientific Research Fund Meeting 2008, Dec, Executive Grant Committee meeting
 - American Heart Association, Scientific Sessions, 2008, Nov, New Orleans “Role of PARP in myocardial hypertrophy”. Also, symposium organizer.
 - 6th Meeting of the International Chair on Cardiometabolic Risk (ICCR), Canada, 2008 “Cardiovascular effects of cannabinoids”
 - Section on Neuroendocrine Immunology & Behavior NIMH/NIH, March 2008 “Interplay of oxidative/nitrosative stress and endocannabinoid system in doxorubicin-induced heart failure”.
 - American Society of Addiction Medicine (ASAM) meeting on April 13, 2008, in Toronto, Canada, “Role of Endocannabinoid System in Cardiovascular Diseases”
 - Experimental Biology Meeting, San Diego, 2008 “Hemodynamic measurements in mice and rats using pressure-volume system.”
 - 3rd International Mitochondria Minisymposium: mitochondria and their proteomics, Natcher Conference Center (Building 45) ♦ Bethesda, Maryland, January 9–11, 2008 “Oxidative/nitrosative stress in various animal models of heart failure.”
 - Cardiovascular Research Group, University of Alberta, Edmonton, Alberta, Canada 2008 “Interplay between NO, superoxide and peroxynitrite in heart failure”
 - Boston Medical Center, Dept of Cardiology 2008 “Endocannabinoid inhibition and its relevance for heart disease, atherosclerosis and cirrhosis”
 - New York Medical College, Dept of Physiol., 2008 “Peroxyntirite is a major mediator of cell death and dysfunction in doxorubicin-induced heart failure and myocardial infarction”

Pal Pacher M.D., Ph.D. - CV

- GW 3rd Annual Scientific Review, Royal Academy of Science, London, 2008. "Cannabinoids and the cardiovascular system"
- The George Washington University, Dept of Cardiology, 2007 "Peroxynitrite is the major trigger of doxorubicin-induced cell death in myocytes and endothelial cells in vivo and in vitro"
- American Heart Association Meeting 2007, Orlando "Title: Role of superoxide, nitric oxide and peroxynitrite in doxorubicin-induced cell death in vitro and in vivo"
- 10th International Conference on Bioactive Lipids in Cancer, Inflammation and Related Diseases 2007 "Role of CB2 cannabinoid receptors in endothelial inflammatory response: implications for ischemia-reperfusion injury, atherosclerosis and cardiovascular aging."
- University Tromso, Faculty of Medicine, Norway 2007; first opponent on PhD defense of Elena Egorina
- CB2 cannabinoid receptors: new vistas, Banff, Canada, 2007 "Role of endocannabinoids and cannabinoid 2 receptor in hepatic ischemia/reperfusion injury"
- International Cannabinoid Research Society Meeting, Saint-Sauveur, Canada, 2007 "Cannabinoid receptor 2 mediates protection against hepatic ischemia/reperfusion injury" "Pharmacological inhibition of cannabinoid-1 receptor protects against doxorubicin-induced cardiotoxicity."
- East Coast PARP 2007 Meeting, Quebec, Canada "Role of PARP in heart failure and angiogenesis"
- NIH Research Festival, 2006; Session Chair "Neural and Neuroendocrine Factors in Shock and Inflammatory Tissue Damage" "Endocannabinoid System: Emerging Target against Ischemic-reperfusion Injury"
- 15th World Congress of Pharmacology, Beijing, China, July 2006 "Pharmacological modulation of oxidative-nitrosative stress and downstream effectors in heart failure."
- International Semmelweis Symposium "Nitric oxide and nitrosative stress in the cardiovascular system", Budapest, Hungary, October 2006; Session Chair; "Nitrosative stress, PARP and chronic heart failure"
- HHS Office of Public Health Emergency Preparedness, August 2006 "PARP inhibition against toxin-induced cardiovascular collapse."
- Pennington Biomedical Research Center, Louisiana State University System, 2006 "Diabetic cardiovascular dysfunction: role of PARP"
- Hungarian Academy of Sciences, August 2005 "Role of peroxynitrite in the contractile dysfunction in doxorubicin-induced heart failure"
- Departments of Human Physiology and Clinical Experimental Research and Pharmacology and Pharmacotherapy, Medical Faculty, Semmelweis University Medical School, Budapest, Hungary, 2005. "New pharmacological strategies against doxorubicin-induced cardiotoxicity"
- 1st Annual INIP Biodefense Workshop, NIH, 2004
- Department of Life Sciences, University of Hertfordshire, UK, October 2004 "Mechanisms of heart failure, role of oxidative stress"
- Centre for Cardiovascular Biology & Medicine, GKT School of Biomedical Sciences, King's College London, Guy's Campus, London SE1 1UL., UK, October 2004 "Role of peroxynitrite and PARP in heart failure"
- Department of Physiology, Ludwig Maximilians University, Munich, Germany, October 2004 "PARP in cardiovascular diseases"
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary, 2004 "Diabetic cardiomyopathy: role of PARP"
- XVIII World Congress International Society for Heart Research, Brisbane, Australia, August 2004 "Role of oxidative and nitrosative stress in various forms of heart failure"
- 9th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine Crete, (Greece), October 14-16, 2004; Session Chair; "Mechanisms of Doxorubicin-induced cardiotoxicity"
- 3rd International conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, (Japan) May, 2004 "Peroxynitrite neutralization protects against doxorubicin-induced heart failure"
- 5th International Congress on Coronary Artery Disease, Florence (Italy), October 2003 "Pharmacological inhibition of PARP as new therapy for chronic heart failure"
- Procter & Gamble, Cincinnati, (USA), 2003 "Application of pressure-volume system in rodents"
- Experimental Biology Meeting (FASEB), New Orleans, (USA), 2002 "Role of PARP in ARDS"
- Semmelweis University, Budapest, Hungary, 2001
- International Society for the Study of Hypertension in Pregnancy (ISSHP) meeting, Kobe, Japan, 1998 "Prolongation of repolarization in postpartum animals: clinical relevance."

Pal Pacher M.D., Ph.D. - CV

- WPA Thematic Conference "Synthesis Between Psychopharmacology and Psychotherapy", Jerusalem, Israel, November 16-21, 1997 "Cardiovascular effects of fluoxetine"

Collaborators (past/present):

NIH:

Dr. **George Kunos**; Scientific Director, NIAAA/NIH;

Dr. **Resat Cinnar**; NIAAA/NIH.

Dr. **Tony Jourdan**, NIAAA/NIH.

Dr. **Byoung Song**; Unit of Molecular Biology, NIAAA/NIH;

Dr. **Bin Gao**; Chief, Laboratory of Liver Biology, NIAAA/NIH.

Dr. **Ted Usdin**; Laboratory of Genetics, National Institute of Mental Health.

Dr. **Esther M. Sternberg**, Director Integrative Neural Immune Program Section on Neuroendocrine Immunology & Behavior, National Institute of Mental Health.

Dr. **Michael J. Iadarola**, chief of the Neuronal Gene Expression Unit, National Institute of Dental and Craniofacial Research.

Drs. **David Wink** and **Murali Krishna Cherukuri**; National Cancer Institute, Radiology Branch

Dr. **Wen Jin Wu**: FDA/CDER

Dr. **Falk W. Lohoff**, Chief, Section on Clinical Genomics and Experimental Therapeutics (CGET)

Extramural:

United States:

Prof. **Benjamin F. Cravat**, Departments of Cell Biology and Chemistry, The Scripps Research Institute, La Jolla, CA;

Dr. **Daniel Nomura**, University of California at Berkeley.

Prof. **Gabor Kalle**, Dept. of Physiology, New York Medical College, Valhalla, New York 10595,

Prof. **Zoltan Ungvari**, University of Oklahoma Health Sciences Center.

Prof. **Gyorgy Hasko**; Department of Surgery, UMD NJ-New Jersey Medical School, Newark, New Jersey.

Dr. **Oleg V. Evgenov**; Department of Anesthesia & Critical Care Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114.

Prof. **Aron Lichtman**, VCU.

Prof **Ken Mackie**, Department of Psychological and Brain Sciences and Program in Neuroscience;

Professor **David Kass**; Johns Hopkins University, Baltimore.

Drs. **Lois E. Smith** and **Zsuzsanna Zsengeller**; Children's Hospital Boston, Harvard Medical School

Prof. **Aristidis Veves**, Beth Israel Deaconess Medical Center, Boston, MA

Prof. **Balaraman Kalyanaraman**, Medical College of Wisconsin

Dr. **Zsuzsanna Zsengeller**, **Isaac E. Stillman**, Department of Pathology, Beth Israel Deaconess Medical Center

Prof **Cecilia Hillard**, Medical College of Wisconsin

Dr. **Thomas Shindler**, Johns Hopkins University

Prof. **Csaba Szabo**, Anesthesiology, UTMB; Univ. of Freiburg, Switzerland

Prof. **Yuri Persidsky**, Temple Univ., Dept. of Pathology; Prof. **Wen-Xing Ding**, Univ of. Kansas, Dept. of Pharmacol, Toxicol & Therapeutics

Europe:

Prof. **Lucas Liaudet**, Critical Care Division, Department of Internal Medicine, University Hospital, Lausanne, Switzerland.

Jon Mabley, School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton UK.

Drs. **Rohini Kuner**; University of Heidelberg, Germany

Drs. **Stefan Engeli** and **Jens Jordan**; Franz Volhard Clinical Research Center, Charité Campus Buch, and HELIOS Klinikum Berlin, Berlin, Germany.

Prof. **Roger Pertwee**, University of Aberdeen, UK

Dr. **Peter Bai**, Univ of Debrecen Hungary

Prof. **Peter Ferdinandy**, Dept. of Pharmacology, Semmelweis University

Prof. **Zoltan Benyo**, Institute of Human Physiology and Clinical Experimental Research, Semmelweis University

Dr. **Peter Hamar**, Semmelweis University, Dept. of Pathophysiology

Semmelweis University, Heart and Vascular Center

Prof. **Mauro Maccarrone**, University of Teramo, Italy.

Prof. **Jürg Gertsch**, University of Bern, Institute of Biochemistry and Molecular Medicine

Drs. **Grether Uwe**, **Juergen Fingerlee**, **Christoph Ulmer**, Hoffman-La Roche, Switzerland

Dr. **Mario van der Stelt**, Leiden University, Netherlands

Prof. **Raphael Mechoulam**; Department of Medicinal Chemistry and Natural Products, Hebrew University Medical Faculty

PEER-REVIEWED ORIGINAL RESEARCH PAPERS (selected from over 350)

1996-2000

1. V Kecskeméti, **P PACHER**, P Nánási, C Pankucsi: Comparative study of cardiac electrophysiological effects of atrial natriuretic peptide *J Mol Cell Biochem* 1996, 160/161:53-59.
2. **P PACHER**, V Kecskeméti, I Balogh, AZ Rónai, G Szalai, B Matkovics: Changes in cardiac electrophysiology, morphology, tissue biochemistry, and vascular reactions in glutathione depleted animals. *J Mol Cell Biochem* 1998;185, 183-190.
3. Z Ungvári, **P PACHER**, V Kecskeméti, L Szollár, A Koller. Increased myogenic tone in skeletal muscle arterioles of diabetic rats. Possible role of increased activity of smooth muscle Ca²⁺ channels and protein kinase C. *Cardiovasc Res* 1999; 43(4), 1018-28.
4. Z Ungvári, **P PACHER**, V Kecskeméti, A Koller. Fluoxetine dilates isolated small cerebral arteries of rats and attenuates constrictions to serotonin, norepinephrine and a voltage dependent Ca²⁺ channel opener. *Stroke* 1999; 30(9), 1949-54.
5. Z Ungvári, **P PACHER**, K Rischák, L Szollár, A Koller. Endothelial dysfunction in isolated arterioles of methionine diet-induced hyperhomocysteinemic rats. *Arterioscler Thromb Vasc Biol* 1999; 19, 1899-1904.
6. **P PACHER**, Z Ungvári, V Kecskeméti, A Koller. Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca²⁺ sensitivity. *Br J Pharmacol* 1999; 127, 740-746.
7. **P PACHER**, Z Ungvári, V Kecskeméti. Cardiac electrophysiological effects of homocystein in isolated rats right ventricular papillary muscles and left atria. *Gen Pharmacol*. 1999; 32,439-443.
8. **P PACHER**, Z Ungvári, P P Nánási, V Kecskeméti. Electrophysiological changes in rat ventricular and atrial myocardium at different stages of experimental diabetes. *Acta Physiol Scand*. 1999; 166, 7-13.
9. **P PACHER**, Z Ungvári, P P Nánási, V Kecskeméti. Electrophysiological changes in rat ventricular and atrial myocardium at different stages of experimental diabetes. *Acta Physiol Scand*. 1999; 166, 7-13.
10. E Kocsis, **P PACHER**, I Posa, E Nieszner, G Pogátsa, MZ Koltai. Hyperglycaemia alters the endothelium-dependent relaxation of canine coronary arteries. *Acta Physiol Scandinavica*. 2000; 169:183-7.
11. Z Ungvári, **P PACHER**, A Koller. Fluoxetine Decreases Arterioles Myogenic Tone by Reducing Smooth Muscle [Ca²⁺]_i. *J Cardiovasc Pharmacol* 2000; 35:849-54.
12. F Deák, B Lasztóczy, **P PACHER**, G Petheö, V Kecskeméti, A Spät. Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. *Neuropharmacology*. 2000, 39:1029-1036.
13. **P PACHER**, J Magyar, P Szigligeti, T Bányász, C Pankucsi, S Korom, Z Ungvári, V Kecskeméti, PP Nánási. Electrophysiological effects of fluoxetine in mammalian cardiac tissues. *Naunyn-Schmiedeberg's Arch Pharmacol*. 2000, 361:67-73.
14. **P PACHER**, Z Bagi, ZL Futó, Z Ungvári, PP Nánási, V Kecskeméti. Cardiac electrophysiological effects of citalopram in guinea pig papillary muscle Comparison with clomipramine. *Gen Pharmacol* 2000; 34:17-23.
15. **P PACHER**, G Csordás, G Hajnoczky. Quantification of calcium signal transmission from the sarco-endoplasmic reticulum to mitochondria. *J Physiology (London)* 2000; 529:553-564.

2001

16. A Marton, **P PACHER**, KG Murthy, ZH Nemeth, G Hasko, C Szabo. Anti-inflammatory effects of inosine in human monocytes, neutrophils and epithelial cells in vitro. *Int J Mol Med* 2001; 8:617-621.
17. **P PACHER**, Z Ungvári, V Kecskeméti, T Friedmann, S Furst. Serotonin reuptake inhibitors fluoxetine and citalopram relax intestinal smooth muscle. *Can J Physiol Pharmacol* 2001; 79:580-584.
18. L Liaudet, J Mabley, G Soriano, **P PACHER**, A Marton, G Hasko, C Szabo. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. *Am J Respir Crit Care Med* 2001; 164:1213-20.
19. G Soriano, **P PACHER**, J Mabley, L Liaudet, C Szabo. Rapid reversal of diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase. *Circ Res* 2001;89(8):684- 91.
20. **P PACHER** & G Hajnoczky. Propagation of the apoptotic signal by mitochondrial waves. *EMBO J* 2001;20:4107-4121.

2002

21. J Magyar, T Bányász, Z Bagi, **P PACHER**, N Szentandrassy, L Fülöp, V Kecskeméti and P P. Nánási. Electrophysiological effects of risperidone in mammalian cardiac cells. *Naunyn-Schmiedeberg's Arch Pharmacol*. 2002; 366(4):350-6.
22. FG Soriano, L Liaudet, E Szabo, L Virag, J Mabley, **P PACHER**, C Szabo. Resistance to acute septic peritonitis in poly (ADP-Ribose) polymerase-1 deficient mice. *Shock* 2002;17(4):286-292.
23. C Szabo, JG Mabley, SM Moeller, R Shimanovich, **P PACHER**, L Virag, FG Soriano, JH Van Duzer, W Williams, AL Salzman, JT Groves. Part I: Pathogenetic Role of Peroxynitrite in the Development of Diabetes and Diabetic Vascular Complications: Studies With FP15, A Novel Potent Peroxynitrite Decomposition Catalyst. *Mol Med* 2002 Oct;8(10):571-80.

24. JG Mabley, L Liaudet, **P PACHER**, GJ Southan, AL Salzman, C Szabo. Part II: Beneficial Effects of the Peroxynitrite Decomposition Catalyst FP15 in Murine Models of Arthritis and Colitis. *Mol Med* **2002** Oct;8(10):581-90.
 25. A Csiszar, G Steff, **P PACHER**, Z Ungvari. Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. *Prostaglandins Leukot Essent Fatty Acids* **2002**;66(5-6):557-8.
 26. G Haskó, JG Mabley, ZH Németh, **P PACHER**, EA Deitch, C Szabó. Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation. *Mol Med* **2002**, 8(9):285-292.
 27. L Liaudet, K Murthy, J Mabley, **P PACHER**, FG Soriano, A.L Salzman, C Szabo. Comparison of Inflammation, Organ Damage, and Oxidant Stress Induced by *Salmonella enterica* Serovar Muenchen Flagellin and Serovar Enteritidis Lipopolysaccharide. *Infect Immun* **2002**; 70: 192-198.
 28. ZH Németh, EA Deitch, C Szabó, JG Mabley, **P PACHER**, Z Fekete, CJ Hauser, and G Haskó. Na⁺/H⁺ exchanger blockade inhibits enterocyte inflammatory response and protects against colitis. *Am J Physiol Gastrointest Liver Physiol* **2002** 283 (1): p. G122-132.
 29. J Mabley, **P PACHER**, AL Salzman, C Szabo. Nicotine reduces the incidence of type I diabetes in mice. *J Pharm Exp Ther* **2002**, 300(3):876-881.
 30. L Liaudet, J Mabley, **P PACHER**, L Virag, FG Soriano, A. Marton, G Hasko, EA Deitch, C Szabo. Inosine exerts a broad range of anti-inflammatory effects in a murine model of acute lung injury. *Ann Surgery* **2002**; 235:568-578.
 31. L Liaudet, **P PACHER**, J Mabley, L Virag, FG Soriano, C Szabo. Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of LPS-induced acute lung inflammation. *Am J Resp Crit Care Med* **2002**, 165:372-377.
 32. MY Kirov, OV Evgenov, VN Kuklin, L Virag, **P PACHER**, GJ Southan, AL Salzman, C Szabo, LJ Bjertnaes. Aerosolized linear polyethylenimine-NONO attenuates endotoxin-induced lung injury in sheep. In press in: *Am J Resp Crit Care Med* **2002**; 166(11):1436-42.
 33. G Szabó, S Bährle, N Stumpf, K Sonnenberg, É Szabó, **P PACHER**, T Csont, R Schulz, TJ Dengler, L Liaudet, GJ Southan, CF Vahl, S Hagl and C Szabó. Poly (ADP-ribose) Polymerase Inhibition Reduces Reperfusion Injury after Heart Transplantation. *Circ Res* **2002**; 11;90(1):100-6.
 34. C Szabó, A Zanchi, K Komjáti, **P PACHER**, AS Krolewski, WC Quist, ES Horton, FW LoGerfo, A Veves. Poly (ADP-ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity. *Circulation* **2002**;106:2680-2686.
 35. **P PACHER**, JG Mabley, FG Soriano, L Liaudet, C Szabó. Poly(ADP-ribose) polymerase activation contributes to the endothelial dysfunction associated with hypertension and aging. *Int J Mol Med* **2002** Jun;9(6):659-664.
 36. **P PACHER**, A Cziráki, L Papp, JG. Mabley, C Szabó. Role of poly(ADP-ribose) polymerase activation in the endotoxin-induced cardiac collapse in rodents. *Biochem Pharmacol.* **2002**;64(12):1785-91. (**IF: 4.89**)
 37. **P PACHER**, JG Mabley, FG Soriano, L Liaudet, K Komjati, C Szabó. Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. *Br J Pharmacol* **2002**, 135(6):1347-50.
 38. **P PACHER**, L Liaudet, P Bai, L Virag, JG Mabley, G Haskó and C Szabó. Activation of poly(ADP-ribose) polymerase contributes to the development of doxorubicin-induced heart failure. *J Pharm Exp Ther* **2002**, 300(3):862-867.
 39. **P PACHER**, L Liaudet, JG Mabley, C Szabó. Pharmacological inhibition of poly(ADP-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. *J Am Coll Cardiol* **2002**, 40/5 pp. 1006-1016.
 40. **P PACHER**, L Liaudet, FG Soriano, JG Mabley, E Szabó and C Szabó. The role of poly(ADP-ribose) polymerase in the development of cardiovascular dysfunction in diabetes mellitus. *Diabetes* **2002**, 51:514-521.
 41. **P PACHER**, AP Thomas, G Hajnoczky. Ca²⁺ Marks: Miniature calcium signals in single mitochondria driven by ryanodine receptors. *PNAS USA*, **2002**, 99: 2380-2385.
- 2003**
42. J Liu, S Batkai, **P PACHER**, J Harvey-White, JA Wagner, BF Cravatt, B Gao, G Kunos. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/ phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. *J Biol Chem.* **2003** 7;278(45):45034-9.
 43. M Begg, FM Mo, L Offertaler, S Batkai, **P PACHER**, RK Razdan, DM Lovinger, G Kunos. G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca²⁺-dependent K⁺ current. *J Biol Chem.* **2003** Nov 14;278(46):46188-94.
 44. AG Minchenko, MJ Stevens, L White, OI Abatan , K Komjati, **P PACHER**, C Szabo, IG Obrosova. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. *FASEB J.* **2003** Aug;17(11):1514-6.
 45. JG Mabley , A Rabinovitch, W Suarez-Pinzon, G Hasko, **P PACHER**, R Power, G Southan, A Salzman A, C Szabo. Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes. *Mol Med.* **2003** Mar-Apr;9(3-4):96-104.
 46. L Liaudet, C Szabo, K Murthy, O Evgenov, **P PACHER**, L Virag, J Mabley, Marton A, FG Soriano, Kirov

Pal Pacher M.D., Ph.D. - CV

- MY, Bjertnaes LJ, AL Salzman. Flagellin from gram-negative bacteria is a potent mediator of acute lung inflammation. *Shock* **2003** Feb;19(2):131-7.
47. JG Mabley, **P PACHER**, L Liaudet, FG Soriano, G Haskó, A Marton, C Szabó and A Salzman. Inosine reduces inflammation and improve survival in a murine model of colitis. *Am J Physiol-Gastrointestinal* **2003** Jan;284(1):G138-44.
48. E Bakondi , M Gonczi , E Szabo, P Bai , **P PACHER**, P Gergely, L Kovacs, J Hunyadi , C Szabo, L Csernoch , L Virag . Role of intracellular calcium mobilization and cell-density-dependent signaling in oxidative-stress-induced cytotoxicity in HaCaT keratinocytes. *J Invest Dermatol.* **2003** Jul;121(1):88-95.
49. J Magyar, Z Rusznák, C Harasztosi, Á Körtvély, **P PACHER**, T Bányász, L Kovács, G Szűcs, PP Nánási and V Kecskeméti. Differential effects of R(-) and S(+) enantiomers of fluoxetine in mammalian neural and cardiac tissues. *Int J Mol Med* **2003** Apr;11(4):535-42.
50. OV Evgenov, **P PACHER**, W Williams, NV Evgenov, JG Mabley ,J Cicila ,ZB Siko ,AL Salzman , C Szabo. Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. *Crit Care Med.* **2003** Oct;31(10):2429-36.
51. JG Mabley, **P PACHER**, G Hasko, A Salzman, Marton A, Wallace R, C Szabo. The adenosine A(3) receptor agonist, N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. *Eur J Pharmacol* **2003** Apr 18;466(3):323-9.
52. **P PACHER**, JG Mabley, L Liaudet, O Evgenov, G Southan, C Szabó and A Salzman. Topical administration of a novel nitric oxide donor, DS1, increases vaginal blood flow in anesthetized rats. *Int J Impot Res.* **2003** Dec;15(6):461-4.
53. **P PACHER**, L Liaudet, P Bai, J G. Mabley, P Kaminski, L Virág, É Szabó, Z Ungvari, MS Wollin, JT Groves, C Szabó. A potent peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. *Circulation* **2003** Feb 18;107(6):896-904.

2004

54. IG Obrosova, AG Minchenko, RN Frank, GM Seigel, Z Zsengeller, **P PACHER**, MJ Stevens, C Szabo. Poly(ADP-Ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor (VEGF) overexpression. *IJMM*, 2004 Jul;14(1):55-64.
55. IG Obrosova, F Li, OI Abatan, K Komjádi, **P PACHER**, C Szabo, MJ Stevens et al. Role for poly (ADP-ribose) polymerase activation in diabetic neuropathy. *Diabetes* **2004** Mar;53(3):711-20.
56. Li F, Szabo C, **PACHER P**, Southan GJ, Abatan OI, Charniauskaya T, Stevens MJ, Obrosova IG. Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy. *Diabetologia* . **2004** Apr;47(4):710-7.
57. Murakami K, Enkhbaatar P, Shimoda K, Cox RA, Burke AS, Hawkins HK, Traber LD, Schmalstieg FC, Salzman AL, Mabley JG, Komjati K, **PACHER P**, Zsengeller Z, Szabo C, Traber DL. Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. *Shock.* **2004** Feb;21(2):126-33.
58. C Szabó, **P PACHER**, Z Zsengellér, A Vaslin, K Komjádi, R Benkő, JG Mabley and M Kollai. Angiotensin II mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. *Mol Med* **2004** Jan-Jun;10(1-6):28-35.
59. Benko R, **PACHER P**, Vaslin A, Kollai M, Szabo C. Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase. *Life Sci.* **2004** Jul 23;75(10):1255-61.
60. S Batkai, **P PACHER**, G Kunos. Cannabinoid antagonist SR141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. *Am J Physiol Heart Circulation Physiol* **2004** Aug;287(2):H595-600.
61. JG Mabley, **P PACHER**, S Goonesekera, GS. Southan and C Szabo. Suppression of intestinal polyposis in *Apc^{min/+}* mice by inhibition of inducible nitric oxide synthase, poly (ADP-ribose) synthetase and a peroxynitrite decomposition catalyst. *Mutation Res* **2004**; 548(1-2):107-16.
62. P Bai, JG Mabley , L Liaudet , L Virag ,C Szabo, **P PACHER**. Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. *Oncology Reports* 11, 2: 505-509, **2004**.
63. **P PACHER**, JG. Mabley, L Liaudet, A Marton, G Hasko, O Evgenov, M Kollai and C Szabó. Left ventricular pressure-volume relationship in a rat model of advanced aging-induced heart failure. *Am J Physiol Heart Circulation Physiol* **2004** Nov;287(5):H2132-2137.
64. **P PACHER**, A Vasslin, R Benkő, JG Mabley, L Liaudet, G Hasko, S Batkai, A Marton, M Kollai, and C Szabo. A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. *JPET* **2004** Nov;311(2):485-491.
65. **P PACHER**, S Batkai, G Kunos. Hemodynamic profile and responsiveness to anandamide of TRPV₁ receptor knock-out mice. *J Physiol London* **2004** Jul 15;558(Pt2):647-657.

66. S Batkai, **P PACHER**, D Osei-Hyiaman, S Radaeva, J Liu, J Harwey-W, L Offertaler, K Mackie, MA Rudd, R Bukoski, G Kunos. Endocannabinoids acting at CB₁ receptors regulate cardiovascular function in hypertension. *Circulation* **2004** Oct 5;110(14):1996-2002. (shared first Author)

2005

67. O Szenczi, P Kemecei, MF.J. Holthuisen, N.A.W. van Riel, G.J. van der Vusse, **P PACHER**, C Szabó, M Kollai, L Ligeti and T Ivanics. Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. *Biochem Pharmacol* **2005** Mar 1;69(5):725-732.
68. P Pascale, M Oddo, **P PACHER** and Lucas Liaudet. Massive rhabdomyolysis following venlafaxine overdose. **2005** *Ther Drug Monit.* Oct;27(5):562-564.
69. Ojaimi C, Li W, Kinugawa S, Post H, Csiszar A, **PACHER P**, Kaley G, Hintze TH. Transcriptional basis for exercise limitation in male eNOS-knockout mice with age: heart failure and the fetal phenotype. *Am J Physiol Heart Circ Physiol.* 2005 Oct;289(4):H1399-407.
70. D Osei-Hyiaman, M DiPetrillo, **P PACHER**, S Radaeva, J Liu, J Harwey-W, S Batkai, L Offertaler, G Kunos. Endocannabinoid activation at hepatic CB₁ receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. *JCI* **2005** May;115(5):1298-1305.
71. IG Obrosova, VR Drel, **P PACHER**, O Ilynska, ZQ Wang, MJ Stevens, MA Yorek. Oxidative-nitrosative stress and PARP activation in experimental diabetic neuropathy: the relation is revisited. *Diabetes* **2005** Dec;54(12):3435-4341.
72. S Engeli, J Böhnke, M Feldpausch, K Gorzelniak, J Janke, S Bátkai, **P PACHER**, FC Luft, AM Sharma, J Jordan. Activation of the Peripheral Endocannabinoid System in Human Obesity. *Diabetes.* **2005** Oct;54(10):2838-2843.
73. B Pesse, S Levrand, F Feihl, B Waeber, **P PACHER** and L Liaudet. Peroxynitrite activates the MEK- ERK 1/2 pathway independently from EGF Receptor, p21^{Ras} and Raf-1 kinase in H9C2 cardiomyocytes. *J Mol Cell Cardiol* **2005** May;38(5):765-775.
74. S Levrand, B Pesse, F Feihl, B Waeber, **P PACHER**, J Rolli, MD Schaller, L Liaudet. Peroxynitrite is a potent inhibitor of NF-kappa B activation triggered by inflammatory stimuli in cardiac and endothelial cell lines. *J Biol Chem.* **2005** Oct 14;280(41):34878-87.
75. Z Nemeth, CS Lutz, B Csoka, EA Deitch, SJ Leibovich, WC Gause, M Tone, **P PACHER**, ES Vizi, G Hasko. Adenosine augments interleukin-10 production by macrophages through an A_{2B} receptor-mediated post-transcriptional mechanism. *J Immunology* 2005 Dec 15;175(12):8260-70.
76. JG. Mabley, **P PACHER**, A Deb, R Wallace, RH Elder, C Szabó. Potential role for 8-oxoguanine DNA glycosylase in regulating inflammation *FASEB J.* **2005** Feb;19(2):290-292.
77. IG Obrosova, **P PACHER**, C Szabo, Z Zsengeller, H Hirooka, MJ Stevens, MA Yorek. Aldose Reductase Inhibition Counteracts Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase Activation in Tissue Sites for Diabetes Complications. *Diabetes.* **2005** Jan;54(1):234-242 (shared first Author).
78. **P PACHER**, Batkai S, Osei-Hyiaman D, Offertaler L, Liu J, Harvey-White J, Brassai A, Jarai Z, Cravatt BF, Kunos G. Hemodynamic profile, responsiveness to anandamide and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. *Am J Physiol Heart Circ Physiol.* **2005** 289(2):H533-541. (Editorial highlight)

2006

79. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, Mo FM, Offertaler L, **PACHER P**, Kunos G, Mechoulam R. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. *Proc Natl Acad Sci U S A.* **2006** Feb 14;103(7):2428-33.
80. ZH Németh, B Csóka, J Wilmanski, D Xu, Q Lu, C Ledent, EA Deitch, **P PACHER**, Z Spolarics, and G Haskó. Adenosine A_{2A} receptor inactivation increases survival in polymicrobial sepsis. *J Immunol* **2006**; 176(9):5616-5626.
81. S Levrand, C Vannay-Bouchiche; B Pesse, **P PACHER**, F Feihl, B Waeber, L Liaudet. Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. *Free Radical Biology and Medicine* **2006**; Sep 15;41(6):886-95.
82. M Blüher, S Engeli, N Klötting, J Berndt, M Fasshauer, S Bátkai, **P PACHER**, MR Schön, J Jordan, M Stumvoll. Dysregulation of the Peripheral and Adipose-Tissue Endocannabinoid System in Human Abdominal Obesity *Diabetes* **2006** Nov;55(11):3053-60.
83. IG Obrosova, VR Drel, AK Kumagai, C Szabo, **P PACHER**, MJ Stevens. Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models. *Diabetologia.* 2006 Oct;49(10):2525-33.
84. N Labinskyy, A Csiszar, J Wu, G Veress, **P PACHER** and Z Ungvari. Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen. *Curr Med Chem* **2006**, 13(9):989-96.

85. **P PACHER**, L Liaudet, JG Mabley, R Benkő, A Cziráki, G Haskó, M Kollai and C Szabo. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. *Int J Mol Med* 2006 Feb;17(2):369-75.
86. M Rajesh, P Mukhopadhyay, S Bátkai, G Godlewski, G Haskó, L Liaudet and **P PACHER**. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. *BBRC* 2006; 350(2):352-357.
87. M Rajesh, P Mukhopadhyay, G Godlewski, S Bátkai, G Haskó, L Liaudet and **P PACHER**. Poly(ADP-ribose) polymerase inhibition decreases angiogenesis. *BBRC* 2006; 350(4):1056-1062.
88. VR Drel, **P PACHER**, MJ Stevens and IG Obrosova. Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells. *Free Radical Biology and Medicine* 2006;40(8):1454-1465.
89. O Ilnytska, VV Lyzogubov, MJ Stevens, VR Drel, N Mashtalir, **P PACHER**, MA Yorek, IG Obrosova. Poly(ADP-ribose) polymerase inhibition alleviates experimental sensory neuropathy. *Diabetes*; 55(6):1686-1694.

2007

90. N Agarwal, **P PACHER**, F Amaya, C Constantin, G Brenner, C Michalski, I Tegeder, G Marsicano, C Marian, S Batkai, MJ Fischer, P Reeh, G. Kunos, B Lutz, M Kress, C J Woolf, R Kuner. Cannabinoids induce analgesia primarily via CB₁ receptors on peripheral nociceptive neurons. *Nature Neurosci.* 2007 Jul;10(7):870-9.
91. B Csóka, ZH Nemeth, L Virag, P Gergely, SJ Leibovich, **P PACHER**, ES Vizi, EA Deitch, G Hasko. A_{2A} adenosine receptors and C/EBPβ are crucially required for IL-10 production by macrophages exposed to E. coli. *Blood* 2007; 110(7):2685-95.
92. S Batkai, P Mukhopadhyay, J Harvey-White, R Kechrid, **P PACHER**, G Kunos. Endocannabinoids Acting at CB₁ Receptors Mediate the Cardiac Contractile Dysfunction in vivo in Cirrhotic Rats. *Am J Physiol Heart Circ Physiol.* 2007 ;293(3):H1689-95.
93. JG Mabley, R Wallace, **P PACHER**, K Murphy, C Szabó. Inhibition of poly (ADP-ribose) polymerase by the active form of vitamin D. *Int J Mol Med.* 2007 Jun;19(6):947-52.
94. VR Drel, **P PACHER**, I Vareniuk, I Pavlov, O Ilnytska, VV Lyzogubov, J Tibrewala, JT Groves and IG Obrosova. A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice. *European Journal of Pharmacology* 2007, Aug 13;569(1-2):48-58.
95. VR Drel, **P PACHER**, I Vareniuk, I Pavlov, O Ilnytska, VV Lyzogubov, SR Bell, JT Groves and IG Obrosova. Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes. *Int J Mol Med.* 2007 ;20(6):783-92.
96. Csóka, ZH. Németh, Z Selmečzy, B Koscsó, **P PACHER**, ES Vizi, EA Deitch and G Haskó. Role of A_{2A} adenosine receptors in regulation of opsonized E. coli -induced macrophage function. *Purinergic Signaling*, 2007;3(4):447-452.
97. S Levrant, **P PACHER**, B Pesse, J Rolli, F Feihl, B Waeber, L Liaudet. Homocysteine induces cell death in H9C2 cardiomyocytes through the generation of peroxynitrite. *Biochem Biophys Res Commun.* 2007 Aug 3;359(3):445-50.
98. ZH Nemeth, D Bleich, B Csóka, **P PACHER**, JG Mabley, ES Vizi, EA Deitch, C Szabo, G Hasko. Adenosine receptor activation ameliorates type 1 diabetes. *FASEB J.* 2007 Aug; 21: 2379 -2388.
99. CW Michalski, T Laukert, **P PACHER**, N Agarwal, F Bergmann, Y Su, S Bátkai, H Friess and R Kuner. Cannabinoids ameliorate pain and reduce disease pathology in acute pancreatitis in the absence of central side-effects. *Gastroenterology* 2007 May;132(5):1968-78.
100. M Rajesh, P Mukhopadhyay, S Batkai, G Hasko, L Liaudet, JW Huffman, A Csiszar, ZI Ungvari, K Mackie, S Chatterjee, and **P PACHER**. Cannabinoid-2 receptor stimulation attenuates TNF α -induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. *Am J Physiol Heart Circ Physiol.* 2007 Oct;293(4):H2210-8.
101. M Rajesh, P Mukhopadhyay, S Batkai, G Hasko, L Liaudet, VR Drel, IG Obrosova, **P PACHER**. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. *Am J Physiol Heart Circ Physiol.* 2007 Jul;293(1):H610-9.
102. Batkai S, Rajesh M, Mukhopadhyay P, Hasko G, Liaudet L, Cravatt BF, Csiszar A, Ungvari ZI, **PACHER P**. Decreased age-related cardiac dysfunction, myocardial nitrate stress, inflammatory gene expression and apoptosis in mice lacking fatty acid amide hydrolase. *Am J Physiol Heart Circ Physiol.* Aug 2007; 293(2):H909-18.
103. Mukhopadhyay P, Rajesh M, Kashiwaya Yoshihiro, Hasko G, **PACHER P**. Simple quantitative detection of mitochondrial superoxide formation in live cells. *Biochem Biophys Res Commun* 2007 Jun 22;358(1):203-8.
104. M Rajesh, H Pan, P Mukhopadhyay, S Bátkai, D Osei-Hyiaman, G Haskó, L Liaudet, B Gao, **P PACHER**. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury.

- by attenuating oxidative stress, inflammatory response and apoptosis. *Journal of Leukocyte Biology* 2007 Dec;82(6):1382-9. (Cover).
105. S Bátkai, D Osei-Hyiaman, M Rajesh, H Pan, P Mukhopadhyay, J Harvey-White, JW. Huffman, B Gao, G Kunos, **P PACHER**. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. *FASEB J*. 2007 Jun;21(8):1788-800.
106. P Mukhopadhyay, M Rajesh, G Haskó, BJ. Hawkins, Madesh M, **P PACHER**. Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. *Nature Protocols* 2007;2(9):2295-301.
107. P Mukhopadhyay, S Bátkai, M Rajesh, N Czipra, J Harvey-White, G Haskó, Z Zsengeller, NP Gerard, L Liaudet, G Kunos, **P PACHER**. Pharmacological inhibition of cannabinoid receptor-1 protects against doxorubicin-induced cardiotoxicity. *J Am Coll Cardiol*. Aug 2007; 50: 528-536. (Editorial highlight+press release).
- 2008**
108. N Horiguchi, L Wang, P Mukhopadhyay, O Park, WI Jeong, F Lafdil, D Osei-Hyiaman, A Moh, XY Fu, **P PACHER**, G Kunos, B Gao. Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury. *Gastroenterology*. 2008 Apr;134(4):1148-58.
109. CW Michalski, FE Oti, M Erkan, F Bergmann, **P PACHER**, Bátkai S, MW Muller, NA Giese, SH Friess and J Kleeff. Cannabinoids in pancreatic cancer: Correlation with survival and pain. *Int J Cancer*. 2008; 122(4):742-50.
110. C Lengyel, L Virág, PP Kovács, A Kristóf, **P PACHER**, E Kocsis, ZM Koltay, PP Nánási, M Tóth, V Kecskeméti, JG Papp, A Varró, N Jost. Role of slow delayed rectifier K⁺-current in QT prolongation in the alloxan-induced diabetic rabbit heart. *Acta Physiol (Oxf)*. 2008 Mar;192(3):359-68.
111. CW Michalski, M Maier, M Erkan, D Sauliunaite, F Bergmann, **P PACHER**, S Batakai, NA Giese, T Giese, H Friess, J Kleeff. Cannabinoids reduce markers of inflammation and fibrosis in pancreatic stellate cells. *PLoS ONE*. 2008 Feb 27;3(2):e1701.
112. A Csiszar, N Labinsky, A Podlutzky, PM Kaminski, MS Wolin, C Zhang, P Mukhopadhyay, **P PACHER**, F Hu, R de Cabo, P Ballabh, Z Ungvari. Vasoprotective Effects of Resveratrol and SIRT1: Attenuation of Cigarette Smoke-induced Oxidative Stress and Pro-inflammatory Phenotypic Alterations. *Am J Physiol* 2008 Jun;294(6):H2721-35.
113. JG Mabley, **P PACHER**, KG Murthy, W Williams, GJ Southan, AL Salzman, C Szabo. The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes. *J Endocrinol*. 2008 Sep;198(3):581-9.
114. VR Drel, **P PACHER**, TK Ali, J Shin, U Julius, AB El-Remessy, IG Obrosova. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. *Int J Mol Med*. 2008 Jun;21(6):667-76.
115. Ungvari Z, Krasnikov BF, Csiszar A, Labinsky N, Mukhopadhyay P, **PACHER P**, Cooper AJ, Podlutzkaya N, Austad SN, Podlutzky A. Testing hypotheses of aging in long-lived mice of the genus *Peromyscus*: association between longevity and mitochondrial stress resistance, ROS detoxification pathways, and DNA repair efficiency. *Age*. 2008 Sep;30(2-3):121-33.
116. S Engeli, K Heusser, J Janke, K Gorzelniak, S Bátkai, **P PACHER**, J Harvey-White, FC Luft, J Jordan. Peripheral endocannabinoid system activity in patients treated with sibutramine. *Obesity (Silver Spring)*. 2008 May;16(5):1135-7.
117. A Csiszar, N Labinsky, V Perez, FA Recchia, A Podlutzky, P Mukhopadhyay, G Losonczy, **P PACHER**, SN Austad, A Bartke, ZI Ungvari. Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. *Am J Physiol Heart Circ Physiol*. 2008 Nov;295(5):H1882-94.
118. DB Fegley, A Holmes, T Riordan, CA Faber, JR Weiss, S Ma, S Batakai, **P PACHER**, A Dobolyi, A Murphy, MW Sleeman, TB Usdin. Increased fear and stress-related anxiety-like behavior in mice lacking TIP39. *Genes Brain Behav*. 2008 Nov;7(8):933-42.
119. Csóka B, Himer L, Selmezy Z, Vizi ES, **PACHER P**, Ledent C, Deitch EA, Spolarics Z, Németh ZH, Haskó G. Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. *FASEB J*. 2008 Oct;22(10):3491-9.
120. **P PACHER**, K Sharma, G Csordás, Y Zhu, G Hajnoczky. Uncoupling of ER-Mitochondrial Calcium Communication by Transforming Growth factor- β . *Am J Physiol Renal Physiol*. 2008 Nov;295(5):F1303-12.
121. M Rajesh, P Mukhopadhyay, G Haskó, **P PACHER**. Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. *Biochem Biophys Res Commun*. 2008 Dec 26;377(4):1248-52.
122. Rajesh M, Mukhopadhyay P, Haskó G, Huffman JW, Mackie K, **PACHER P**. CB2 cannabinoid receptor agonists attenuate TNF- α -induced human vascular smooth muscle cell proliferation and migration. *Br J Pharmacol*. 2008 Jan;153(2):347-57.

123. KH Moon, BL Hood, P Mukhopadhyay, R Mohanraj, MA Abdelmegeed, YI Kwon, TP Conrads, TD Veenstra, BJ Song, **P PACHER**. Oxidative Inactivation of Key Mitochondrial Proteins Leads to Dysfunction and Injury in Hepatic Ischemia Reperfusion. *Gastroenterology*. 2008 Oct;135(4):1344-57.
124. **P PACHER**, T Nagayama, P Mukhopadhyay, S Bátkai & DA Kass. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. *Nature Protocols* 2008; 3, 1422-1434.

2009

125. G Godlewski, L Offertáler, D Osei-Hyiaman, FM Mo, J Harvey-White, J Liu, MI Davis, L Zhang, RK Razdan, G Milman, **P PACHER**, P Mukhopadhyay, DM Lovinger, G Kunos. The endogenous brain constituent N-arachidonoyl L-serine is an activator of large conductance Ca²⁺-activated K⁺ channels. *J Pharmacol Exp Ther*. 2009 Jan;328(1):351-61.
126. JG Mabley, **P PACHER**, C Szabo. Activation of the cholinergic anti-inflammatory pathway reduces ricin-induced mortality and organ failure in mice. *Mol Med*. 2009 May-Jun;15(5-6):166-72.
127. Mabley JG, **PACHER P**, Murthy KG, Williams W, Southan GJ, Salzman AL, Szabo C. The novel inosine analogue, INO-2002, exerts an anti-inflammatory effect in a murine model of acute lung injury. *Shock*. 2009 Sep;32(3):258-62.
128. Nicolescu AC, Holt A, Kandasamy AD, **PACHER P**, Schulz R. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. *Biochem Biophys Res Commun*. 2009 Oct 2;387(4):646-50.
129. N Labinskyy, P Mukhopadhyay, J Toth, G Szalai, M Veres, G Losonczy, JT Pinto, **P PACHER**, P Ballabh, A Podlutzky, SN Austad, A Csiszar, ZI Ungvari. Longevity is associated with increased vascular resistance to high glucose-induced oxidative stress and inflammatory gene expression in P. leucopus. *Am J Physiol Heart Circ Physiol*. 2009 Apr;296(4):H946-56.
130. Csiszar A, Podlutzky A, Wolin MS, Losonczy G, **PACHER P**, Ungvari Z. Oxidative stress and accelerated vascular aging: implications for cigarette smoking. *Front Biosci*. 2009 Jan 1;14:3128-44.
131. Pan H, Shen Z, Mukhopadhyay P, Wang H, **PACHER P**, Qin X, Gao B. Anaphylatoxin C5a Contributes to the Pathogenesis of Cisplatin-induced Nephrotoxicity. *Am J Physiol Renal Physiol*. 296(3):F496-504.
132. Vareniuk I, **PACHER P**, Pavlov IA, Drel VR, Obrosova IG. Peripheral neuropathy in mice with neuronal nitric oxide synthase gene deficiency. *Int J Mol Med*. 2009 May;23(5):571-80.
133. Helyar SG, Patel B, Headington K, El Assal M, Chatterjee PK, **PACHER P**, Mabley JG. PCB-induced endothelial cell dysfunction: Role of poly(ADP-ribose) polymerase. *Biochem Pharmacol*. 78(8): 959-65, 2009.
134. Csiszar A, Labinskyy N, Pinto J, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, **PACHER P**, Zhang C, Ungvari Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. *Am J Physiol Heart Circ Physiol* 2009 Jul;297(1):H13-20.
135. Labinskyy N, Mukhopadhyay P, Pinto J, Ballabh P, Zhang C, **PACHER P**, Csiszar A, Ungvari Z. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. *Am J Physiol Heart Circ Physiol* 297(5):H1876-81, 2009.
136. Madesh M, Zong WX, Hawkins BJ, Ramasamy S, Venkatachalam T, Mukhopadhyay P, Doonan PJ, Irrinki KM, Rajesh M, **PACHER P**, Thompson CB. Execution of superoxide-induced cell death by the proapoptotic Bcl-2-related proteins Bid and Bak. *Mol Cell Biol*. 2009 Jun;29(11):3099-112.
137. Sovershaev MA, Egorina EM, Hansen JB, Østerud B, **PACHER P**, Stasch JP, and Evgenov OV. Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor. *Arterioscler Thromb Vasc Biol*. 29(10):1578-86, 2009.
138. B Csóka, ZH Németh, P Mukhopadhyay, Z Spolarics, M Rajesh, S Federici, EA Deitch, S Bátkai, **P PACHER**, G Haskó. CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. (co-corresponding Author/PI) *PLoS One*. 2009 Jul 29;4(7):e6409.
139. Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B, Haskó G, **PACHER P**. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation and cell death. *J Pharmacol Exp Ther*. 2009; 328(3):708-14.
140. Rajesh M, Mukhopadhyay P, Bátkai S, Mukhopadhyay B, Patel V, Haskó G, Szabó C, Mabley JG, Liaudet L, **PACHER P**. Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. *J Cell Mol Med* DOI: Aug;13(8B):2330-41, 2009.
141. P Mukhopadhyay, Rajesh M, S Bátkai, K Yoshihiro, G Haskó, L Liaudet, C Szabó and **P PACHER**. Role of superoxide, nitric oxide and peroxynitrite in doxorubicin-induced cell death *in vivo* and *in vitro*. *Am J Physiol Heart Circ Physiol*. 2009 May;296(5):H1466-83 (Highlighted by the Society for Free Radical Biology and Medicine newsletter, among the top 10 cited in AJP Heart since 2009).

2010

142. N Horiguchi, M Andrew, W Hua, F Lafdil, M Rajesh, P Mukhopadhyay, P Ogyi, **P PACHER**, B Gao. Dissociation of liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell specific STAT3 knockout mice. *Hepatology* May;51(5):1724-34.
143. AM Miller, H Wang, O Park, N Horiguchi, F Lafdil, P Mukhopadhyay, A Moh, XY Fu, G Kunos, **P PACHER**, B Gao. Anti-inflammatory and anti-apoptotic roles of endothelial cell STAT3 in alcoholic liver injury. *Alcohol Clin Exp Res*. Apr;34(4):719-25.
144. P Mukhopadhyay, S Mukherjee, K Ahsan, A Bagchi, **P PACHER**, D. Das. Restoration of Altered

- MicroRNA Expression in the Ischemic Heart with Resveratrol. *PLoS One* 2010 Dec 23;5(12):e15705.
145. L Himer, B Csóka, Z Selmeczy, B Koscs, T Pócsa, **P PACHER**, ZH Németh, EA Deitch, ES Vizi, BN Cronstein, G Haskó. Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death. *FASEB J*. 2010 Aug;24(8):2631-40.
146. B Csóka, ZH Németh, P Rosenberger, HK Eltzschig, Z Spolarics, P Pacher, Z Selmeczy, B Koscsó, L Himer, ES Vizi, MR Blackburn, EA Deitch, G Haskó. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. *J Immunol*. 2010 Jul 1;185(1):542-50.
147. Obrosova IG, Maksimchyk Y, **PACHER P**, Agardh E, Smith ML, El-Remessy AB, Agardh CD. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. *Int J Mol Med*. 2010 Jul;26(1):135-42.
148. Rolli J, Loukili N, Levrant S, Rosenblatt-Velin N, Rignault-Clerc S, Waeber B, Feihl F, **Pacher P**, Liaudet L. Bacterial flagellin elicits widespread innate immune defense mechanisms, apoptotic signaling, and a sepsis-like systemic inflammatory response in mice. *Crit Care*. 2010;14(4):R160.
149. Jianhui L, Rosenblatt-Velin N, Loukili N, **Pacher P**, Feihl F, Waeber B, Liaudet L. Endotoxin impairs cardiac hemodynamics by affecting loading conditions but not by reducing cardiac inotropism. *Am J Physiol Heart Circ Physiol*. 2010 Aug;299(2):H492-501.
150. Rolli J, Rosenblatt-Velin N, Li J, Loukili N, Levrant S, **Pacher P**, Waeber B, Feihl F, Ruchat P, Liaudet L. Bacterial flagellin triggers cardiac innate immune responses and acute contractile dysfunction. *PLoS One*. 2010 Sep 13;5(9):e12687.
151. N Loukili, N Rosenblatt-Velin N, J Rolli, S Levrant, F Feihl, B Waeber, **P PACHER**, L Liaudet. Oxidants positively or negatively regulate nuclear factor kappa B in a context-dependent manner. *J Biol Chem*. 2010 May 21;285(21):15746-52.
152. M Rajesh, P Mukhopadhyay, G Haskó, L Liaudet, K Mackie, **P PACHER**. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent MAPK activation and cell death in human coronary artery endothelial cells. *Br J Pharmacol* 2010 Jun;160(3):688-700.
153. P Mukhopadhyay, H Pan, M Rajesh, S Bátkai, V Patel, J Harvey-White, B Mukhopadhyay, G Haskó, B Gao, K Mackie, **P PACHER**. CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation, and cell death in a murine nephropathy model. *Br J Pharmacol* 2010 Jun;160(3):657-68.
154. P Mukhopadhyay, M Rajesh, S Bátkai, V Patel, Y Kashiwaya, L Liaudet, OV Evgenov, K Mackie, G Haskó, **P PACHER**. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. *Cardiovasc Res*. 2010 Mar 1;85(4):773-84.
155. P Mukhopadhyay, M Rajesh, H Pan, V Patel, B Mukhopadhyay, S Bátkai, B Gao, G Haskó, **P PACHER**. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress and cell death in nephropathy. *Free Radic Biol Med*. 2010; Febr 48 (3):457-467.
156. M Rajesh, P Mukhopadhyay, S Bátkai, V Patel, K Saito, S Matsumoto, Y Kashiwaya, B Horváth, B Mukhopadhyay, L Becker, G Haskó, L Liaudet, DA Wink, A Veves, R Mechoulam, **P PACHER**. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy. *J Am Coll Cardiol*. 2010 Dec; 56(25): 2115-2125.
- 2011**
157. R Chandra, S Federici, ZH Németh, B Horváth, **P PACHER**, G Haskó, EA Deitch, Z Spolarics. Female X-Chromosome Mosaicism for NOX2 Deficiency Presents Unique Inflammatory Phenotype and Improves Outcome in Polymicrobial Sepsis. *J Immunol*. 2011 Jun 1;186(11):6465-73.
158. VR Drel, **P PACHER**, R Stavniichuk, W Xu, J Zhang, TM Kuchmerovska, B Slusher, IG Obrosova. Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice. *Int J Mol Med*. 2011 Oct;28(4):629-35.
159. J Mabley, S Gordon, **P PACHER**. Nicotine Exerts an Anti-inflammatory Effect in a Murine Model of Acute Lung Injury. *Inflammation*. 2011 Aug;34(4):231-7.
160. G Haskó, B Csóka, B Koscsó, R Chandra, **P PACHER**, LF Thompson, EA Deitch, Z Spolarics, L Virág, P Gergely, RH Rolandelli, ZH Németh. Ecto-5'-Nucleotidase (CD73) Decreases Mortality and Organ Injury in Sepsis. *J Immunol*. 2011 Oct 15;187(8):4256-67.
161. A Szebeni, N Szentandrassy, **P PACHER**, J Simkó, PP Nánási, V Kecskeméti. Can the electrophysiological action of rosiglitazone explain its cardiac side effects? *Curr Med Chem*. 2011;18(24):3720-8.
162. R Y Gao, P Mukhopadhyay, M Rajesh, H Wang, B Horvath, S Yin, **P PACHER**. Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytes. *Mol Med Reports* 2011; 4(1): 151-155.
163. N Loukili, N Rosenblatt-Velin, J Li, S Clerc, **P PACHER**, F Feihl, B Waeber, L Liaudet. Peroxynitrite induces HMGB1 release by cardiac cells in vitro and HMGB1 upregulation in the infarcted myocardium in vivo. *Cardiovasc Res*. 2011 Feb 15;89(3):586-94.
164. P Mukhopadhyay, B Horváth, M Rajesh, S Matsumoto, K Saito, S Bátkai, V Patel, G Tanchian, RY Gao, BF Cravatt, G Haskó, **P PACHER**. Fatty acid amide hydrolase is a key regulator of the endocannabinoid-induced myocardial tissue injury. *Free Radic Biol Med*. 2011;50(1):179-95.
165. P Mukhopadhyay, M Rajesh, B Horváth, S Bátkai, O Park, O Tanashian, RY Gao, V Patel, DA Wink, L

Pal Pacher M.D., Ph.D. - CV

- Liaudet, G Haskó, R Mechoulam, **P PACHER**. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. *Free Radic Biol Med*. 2011 50(10):1368-81.
166. A. B. El-Remessy, M. Rajesh, P. Mukhopadhyay, B. Horváth, V. Patel, M. M. H. Al-Gayyar, B. A. Pillai and **P. PACHER**. Cannabinoid 1 receptor activation contributes to the vascular inflammation and cell death in diabetic retinopathy. *Diabetologia* 2011;54(6):1567-78.
167. Guerrero-Beltrán CE, Mukhopadhyay P, Béla Horváth, Rajesh M, T Edilia, García-Torres I, Pedraza-Chaverri J, **P PACHER**. Sulforaphane, a natural constituent of broccoli, prevents cell death and inflammation in nephropathy. *J Nutr Biochem* 2012 May;23(5):494-500.
168. B Horvath, L Magid, M Partha, B Sandor, M Rajesh, O Park, G Tanchian, R Gao, C Goodfellow, M Glass, R Mechoulam, **P PACHER**. A new cannabinoid 2 receptor agonist HU-910 attenuates oxidative stress, inflammation, and cell death associated with hepatic ischemia/reperfusion injury. *Br J Pharmacol*. 2012 Apr;165(8):2462-2478.
- 2012**
169. Koscsó B, Csóka B, Selmeczy Z, Himer L, **Pacher P**, Virág L, Haskó G. Adenosine Augments IL-10 Production by Microglial Cells through an A2B Adenosine Receptor-Mediated Process. *J Immunol. J Immunol*. 2012 Jan 1;188(1):445-53.
170. S Cai, S Batra, N Wakamatsu, **P PACHER**, S Jeyaseelan. NLRC4 Inflammasome-Mediated Production of IL-1 β Modulates Mucosal Immunity in the Lung against Gram-Negative Bacterial Infection. *J Immunol*. 2012 Jun 1;188(11):5623-35.
171. B Csóka, Z Selmeczy, B Koscsó, ZH Németh, **P PACHER**, PJ Murray, D Kepka-Lenhart, SM. Morris, Jr., WC Gause, SJ Leibovich, and G Haskó. Adenosine promotes alternative macrophage activation via A_{2A} and A_{2B} receptors. *FASEB J* 2012 Jan;26(1):376-86.
172. G Balamayooran, S Batra, B Theivanthiran, S Cai, **P PACHER**, S Jeyaseelan. Intrapulmonary G-CSF Rescues Neutrophil Recruitment to the Lung and Neutrophil Release to Blood in Gram-Negative Bacterial Infection in MCP-1^{-/-} Mice. *J Immunol*. 2012 Dec 15;189(12):5849-59.
173. S Lupachyk, R Stavniichuk, JI Komissarenko, VR Drel, AA Obrosof, AB El-Remessy, **P PACHER**, Obrosova IG. Na⁺/H⁺-exchanger-1 inhibition counteracts diabetic cataract formation and retinal oxidative-nitrative stress and apoptosis. *Int J Mol Med*. 2012 Jun;29(6):989-98
174. S Engeli, M Blüher, R Jumpertz, T Wiesner, H Wirtz, A Bosse-Henck, M Stumvoll, S Batkai, **P PACHER**, J Harvey-White, G Kunos, J Jordan. Circulating anandamide and blood pressure in patients with obstructive sleep apnea. *J Hypertens*. 2012 Dec;30(12):2345-51
175. F Molica, C M Matter, F Burger, G Pelli, S Lenglet, A Zimmer, **P PACHER**, S Steffens. The cannabinoid receptor CB₂ protects against balloon-induced neointima formation. *AJP Heart* 2012 Mar;302(5):H1064-74.
176. B Sandor, M Partha, B Horvath, M Rajesh, R Gao, A Mahadeva, M Amere, N Battista, A Lichtman, L Gauson, M Maccarrone, R Pertwee, **P. PACHER**. Δ 8-Tetrahydrocannabivarin protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress and inflammatory response involving CB₂ receptors. *Br J Pharmacol*. 2012 Apr;165(8):2450-2461.
177. ZK Zsengellér, L Ellezian, D Brown, B Horváth, P Mukhopadhyay, B Kalyanaraman, SM Parikh, SA Karumanchi, IE Stillman and **P PACHER**. Cisplatin Nephrotoxicity Involves Mitochondrial Injury with Impaired Tubular Mitochondrial Enzyme Activity. *J Histochem Cytochem* 2012, Jul;60(7):521-9.
178. P Mukhopadhyay, B Horváth, M Kechrid, G Tanchian, M Rajesh, AS Naura, AH Boulares, **PPACHER**. 2. Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. *Free Radic Biol Med*. 2011 Nov 1;51(9):1774-88.
179. P Mukhopadhyay, B Horváth, Z Zsengellér, J Zielonka, G Tanchian, E Holovac, M Kechrid, V Patel, IE Stillman, SM Parikh, J Joseph, B Kalyanaraman, **P PACHER**. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. *Free Radic Biol Med*. 2012 Jan 15;52(2):497-506.
180. P Mukhopadhyay, B Horváth, Z Zsengellér, S Batkai, Z Cao, M Kechrid, E Holovac, K Erdélyi, G Tanchian, L Liaudet, IE Stillman, J Joseph, B Kalyanaraman and **P PACHER**. Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially-targeted antioxidants. *Free Radic Biol Med*. 2012;53(5):1123-38.
181. S Batkai, P Mukhopadhyay, B Horváth, M Rajesh, R Y Gao, A Mahadevan, M Amere, N Battista, AH Lichtman, LA Gauson, M Maccarrone, RG Pertwee, **P PACHER**. Δ 8-Tetrahydrocannabivarin prevents hepatic ischaemia/ reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB₂ receptors *Br J Pharmacol*. 2012;165(8):2450-61.
182. B Horvath, P Mukhopadhyay, M Kechrid, V Patel, G Tanashian, DA Wink, J Gertsch, **P PACHER**. β -caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor dependent manner. *Free Radic Biol Med*. 2012 Apr 15;52(8):1325-33.
183. M Rajesh, S Batkai, M Kechrid, P Mukhopadhyay, W-S Lee, B Horvath, E Holovac, R Cinar, L Liaudet, K Mackie, G Haskó, **P PACHER**. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. *Diabetes* 2012 Mar;61(3):716- 27). Highlighted

2013

184. MN Silverman, P Mukhopadhyay, E Belyavskaya, LH Tonelli, BD Revenis, JH Doran, BE Ballard, J Tam, **P PACHER**, EM Sternberg. Glucocorticoid receptor dimerization is required for proper recovery of LPS-induced inflammation, sickness behavior and metabolism in mice. *Mol Psychiatry*. 2013 Sep;18(9):1006-17
185. Iring A, Ruisanchez E, Leszl-Ishiguro M, Horváth B, Benkő R, Lacza Z, Járαι Z, Sándor P, Di Marzo V, **PACHER P**, Benyó Z. Role of endocannabinoids and cannabinoid-1 receptors in cerebrocortical blood flow regulation. *PLoS One*. 2013;8(1):e53390. doi:10.1371/journal.pone.0053390.
186. Molica F, Burger F, Thomas A, Staub C, Tailleux A, Staels B, Pelli G, Zimmer A, Cravatt B, Matter CM, **PACHER P**, Steffens S. Endogenous cannabinoid receptor CB1 activation promotes vascular smooth-muscle cell proliferation and neointima formation. *J Lipid Res*. 2013 May;54(5):1360-8.
187. Koscsó B, Trepakov A, Csóka B, Németh ZH, **PACHER P**, Eltzhig HK, Haskó G. Stimulation of A2B adenosine receptors protects against trauma-hemorrhagic shock-induced lung injury. *Purinergic Signal*. 2013 Sep;9(3):427-32.
188. Erdélyi K, **PACHER P**, Virág L, Szabó C. Role of poly(ADP-ribosyl)ation in a 'two-hit' model of hypoxia and oxidative stress in human A549 epithelial cells in vitro. *Int J Mol Med*. 2013 Aug;32(2):339-46.
189. Koscsó B, Csóka B, Kókai E, Németh ZH, **PACHER P**, Virág L, Leibovich SJ, Haskó G. Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages. *J Leukoc Biol*. 2013 Dec;94(6):1309-15.
190. Li J, Loukili N, Rosenblatt-Velin N, **PACHER P**, Feihl F, Waeber B, Liaudet L. Peroxynitrite is a key mediator of the cardioprotection afforded by ischemic postconditioning in vivo. *PLoS One*. 2013 Jul 10;8(7):e70331.
191. ElZarrad MK, Mukhopadhyay P, Mohan N, Hao E, Dokmanovic M, Hirsch DS, Shen Y, **PACHER P**, Wu WJ. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. *PLoS One*. 2013 Nov 8;8(11):e79543.
192. Rom S, Zuluaga-Ramirez V, Dykstra H, Reichenbach NL, **PACHER P**, Persidsky Y. Selective activation of cannabinoid receptor 2 in leukocytes suppresses their engagement of the brain endothelium and protects the blood-brain barrier. *Am J Pathol*. 2013 Nov;183(5):1548-58. Editorial Highlight
193. Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdélyi K, Hao E, Holovac E, Haskó G, Cravatt BF, Nomura DK, **PACHER P**. Monoacylglycerol Lipase Controls Endocannabinoid and Eicosanoid Signaling and Hepatic Injury in Mice. *Gastroenterology*. 2013 Apr;144(4):808-817.e15

2014

194. Csóka B, Koscsó B, Tőro G, Kókai E, Virág L, Németh ZH, **PACHER P**, Bai P, Haskó G. A2B adenosine receptors prevent insulin resistance by inhibiting adipose tissue inflammation via maintaining alternative macrophage activation. *Diabetes*. 2014 Mar;63(3):850-66.
195. Jourdan T, Szanda G, Rosenberg AZ, Tam J, Earley BJ, Godlewski G, Cinar R, Liu Z, Liu J, Ju C, **PACHER P**, Kunos G. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. *Proc Natl Acad Sci U S A*. 2014 Dec 16;111(50):E5420-8.
196. Mukhopadhyay P, Rajesh M, Cao Z, Horváth B, Park O, Wang H, Erdelyi K, Holovac E, Wang Y, Liaudet L, Hamdaoui N, Lafdil F, Haskó G, Szabo C, Boulares AH, Gao B, **PACHER P**. Poly (ADP- ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. *Hepatology*. 2014 May;59(5):1998-2009.

2015

197. Lugin J, Parapanov R, Rosenblatt-Velin N, Rignault-Clerc S, Feihl F, Waeber B, Müller O, Vergely C, Zeller M, Tardivel A, Schneider P, **PACHER P**, Liaudet L. IL-1 α Is a Crucial Danger Signal Triggering Acute Myocardial Inflammation during Myocardial Infarction. *J Immunol*. 2015 Jan 15;194(2):499-503 (Cutting Edge Paper).
198. Szalay CI, Erdélyi K, Kökény G, Lajtár E, Godó M, Révész C, Kaucsár T, Kiss N, Sárközy M, Csont T, Krenács T, Szénási G, **PACHER P**, Hamar P. Oxidative/Nitrative Stress and Inflammation Drive Progression of Doxorubicin-Induced Renal Fibrosis in Rats as Revealed by Comparing a Normal and a Fibrosis-Resistant Rat Strain. *PLoS One*. 2015 Jun 18;10(6):e0127090. doi: 10.1371/journal.pone.0127090. eCollection 2015
199. Csóka B, Németh ZH, Tőro G, Koscsó B, Kókai E, Robson SC, Enjyoji K, Rolandelli RH, Erdélyi K, **PACHER P**, Haskó G. CD39 improves survival in microbial sepsis by attenuating systemic inflammation. *FASEB J*. 2015 Jan;29(1):25-36. (Cover highlight)
200. Csóka B, Németh ZH, Tőro G, Idzko M, Zech A, Koscsó B, Spolarics Z, Antonioli L, Cseri K, Erdélyi K, **PACHER P**, Haskó G. Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. *FASEB J*. 2015 Sep;29(9):3626-37. doi: 10.1096/fj.15-272450.
201. Bronova I, Smith B, Aydogan B, Weichselbaum RR, Vemuri K, Erdelyi K, Makriyannis A, **PACHER P**, Berdyshev EV. Protection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1. *Am J Respir Cell Mol Biol*. 2015 Oct;53(4):555-62. doi: 10.1165/rcmb.2014-

- 03310C.
202. Godlewski G, Jourdan T, Szanda G, Tam J, Resat Cinar, Harvey-White J, Liu J, Mukhopadhyay B, **PACHER P**, Ming Mo F, Osei-Hyiaman D, George Kunos. Mice lacking GPR3 receptors display late-onset obese phenotype due to impaired thermogenic function in brown adipose tissue. *Sci Rep*. 2015 Oct 12;5:14953. doi: 10.1038/srep14953.
203. Xu MJ, Cai Y, Wang H, Altamirano J, Chang B, Bertola A, Odena G, Lu J, Tanaka N, Matsusue K, Matsubara T, Mukhopadhyay P, Kimura S, **PACHER P**, Gonzalez FJ, Bataller R, Gao B. *Gastroenterology*. 2015 Oct;149(4):1030-41.e6. doi:10.1053/j.gastro.2015.06.009.
204. Hao E, Mukhopadhyay P, Cao Z, Erdélyi K, Holovac E, Liaudet L, Lee WS, Haskó G, Mechoulam R, **PACHER P**. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. *Mol Med*. 2015; 21:38-45doi: 10.2119/molmed.2014.00261.

2016

205. Yan H, Endo Y, Shen Y, Rotstein D, Dokmanovic M, Mohan N, Mukhopadhyay P, Gao B, **PACHER P**, Wu WJ. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. *Mol Cancer Ther*. 2016 Mar;15(3):480-90. doi: 10.1158/1535-7163.MCT-15-0580. PMID:26712117
206. Cinar R, Iyer MR, Liu Z, Cao Z, Jourdan T, Erdelyi K, Godlewski G, Szanda G, Liu J, Park JK, Mukhopadhyay B, Rosenberg AZ, Liow JS, Lorenz RG, **PACHER P**, Innis RB, Kunos G. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. *JCI Insight* 2016 Jul 21;1(11). pii: e87336.
207. Koncsos G, Varga ZV, Baranyai T, Boengler K, Rohrbach S, Li L, Schlüter KD, Schreckenberger R, Radovits T, Oláh A, Mátyás C, Lux Á, Al-Khrasani M, Komlódi T, Bukosza N, Máthé D, Deres L, Barteková M, Rajtkó T, Adameová A, Szigeti K, Hamar P, Helyes Z, Tretter L, **PACHER P**, Merkely B, Giricz Z, Schulz R, Ferdinandy P. Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress. *Am J Physiol Heart Circ Physiol*. 2016 Oct 1;311(4):H927-H943. doi: 10.1152/ajpheart.00049.2016. PMID:27521417
208. Rom S, Zuluaga-Ramirez V, Reichenbach NL, Dykstra H, Gajghate S, **PACHER P**, Persidsky Y. PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier. *J Neuroinflammation*. 2016 Sep 27;13(1):254.
209. Mukhopadhyay P, Baggelaar M, Erdelyi K, Cao Z, Cinar R, Fezza F, Ignatowska-Janlowska B, Wilkerson J, van Gils N, Hansen T, Ruben M, Soethoudt M, Heitman L, Kunos G, Maccarrone M, Lichtman A, **PACHER P**, Van der Stelt M ([shared corresponding author](#)). The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin- induced nephrotoxicity. *Br J Pharmacol*. 2016 Feb;173(3):446-58. doi: 10.1111/bph.13338. Epub 2016 Jan 15.
210. Lee WS, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, Haskó G, Čiháková D, Mechoulam R, **PACHER P**. Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. *Mol Med*. 2016 Jan 8. doi: 10.2119/molmed.2016.00007. [Epub ahead of print]
211. Mátyás C, Varga ZV, Mukhopadhyay P, Paloczi J, Lajtos T, Erdelyi K, Nemeth BT, Nan M, Haskó G, Gao B, **PACHER P**. Chronic plus binge ethanol feeding induces myocardial oxidative stress, mitochondrial and cardiovascular dysfunction and steatosis. *Am J Physiol Heart Circ Physiol*. 2016 Jun 1;310(11):H1658-70. doi: 10.1152/ajpheart.00214.2016. PMID:27106042 [Editorial highlight](#)

2017

212. Petrucci V, Chicca A, Glasmacher S, Paloczi J, Cao Z, **PACHER P**, Gertsch J. Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. *Sci Rep*. 2017 Aug 25;7(1):9560. doi: 10.1038/s41598-017-09808-8.
213. Csóka B, Törő G, Vindeirinho J, Varga ZV, Koscsó B, Németh ZH, Kókai E, Antonioli L, Suleiman M, Marchetti P, Cseri K, Deák Á, Virág L, **PACHER P**, Bai P, Haskó G. A2A adenosine receptors control pancreatic dysfunction in high-fat-diet induced obesity. *FASEB J*. 2017 Nov;31(11):4985-4997
214. Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, **PACHER P**, Kunos G. Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis. *J Med Chem*. 2017 Feb 9;60(3):1126-1141.
215. Wang W, Xu MJ, Cai Y, Zhou Z, Cao H, Mukhopadhyay P, **PACHER P**, Zheng S, Gonzalez FJ, Gao B. Inflammation is independent of steatosis in a murine model of steatohepatitis. *Hepatology*. 2017 Jul;66(1):108-123.
216. Ramirez T, Li YM, Yin S, Xu MJ, Feng D, Zhou Z, Zang M, Mukhopadhyay P, Varga ZV, **PACHER P**, Gao B, Wang H. Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression. *J Hepatol*. 2017 Mar;66(3):601-609. doi: 10.1016/j.jhep.2016.11.004.
217. Varga ZV, Pipicz M, Baán JA, Baranyai T, Koncsos G, Leszek P, Kuśmierczyk M, Sánchez-Cabo F, García-Pavía P, Brenner GJ, Giricz Z, Csont T, Mandler L, Lara-Pezzi E, **Pacher P**, Ferdinandy P. Alternative Splicing of NOX4 in the Failing Human Heart. *Front Physiol*. 2017 Nov 22;8:935. doi: 10.3389/fphys.2017.00935. (Co corresponding Author)

218. Wang Y, Mukhopadhyay P, Cao Z, Wang H, Feng D, Haskó G, Mechoulam R, Gao B, **PACHER P**. Cannabidiol attenuates alcohol-induced liver steatosis, metabolic dysregulation, inflammation and neutrophil-mediated injury. *Sci Rep*. 2017 Sep 21;7(1):12064. doi: 10.1038/s41598-017-10924-8.
219. Soethoudt M, Grether U, Fingerle J, Grim TJ, Fezza F, de Petrocellis L, Ullmer C, Rothenhäusler B, Perret C, van Gils N, Finlay D, MacDonald C, Chicca A, Gens MD, Stuart J, de Vries H, Mastrangelo N, Xia L, Alachouzos G, Baggelaar MP, Martella A, Mock ED, Deng H, Heitman LH, Connor M, Di Marzo V, Gertsch J, Lichtman AH, Maccarrone M, **PACHER P**, Glass M & van der Stelt M. Cannabinoid CB2 Receptor Ligand Profiling Reveals Biased Signaling and Off-target Activity: Implications for Drug Discovery. *Nat Commun*. 2017 Jan 3;8:13958. doi: 10.1038/ncomms13958. (shared senior author)
220. Mukhopadhyay P, Horvath B, Rajesh M, Varga Z, Gariani K, Ryu D, Cao Z, Holovac E, Park O, Zhou Z, Xu MJ, Wang W, Godlewski G, Paloczi J, Nemeth B, Persidsky Y, Liaudet L, Hasko G, Boulares AH, Auwerx J, Gao B, **PACHER P**. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. *J Hepatol*. 2017 Mar;66(3):589-600. Highlight in Nature Reviews Gastroenterology & Hepatology2017Jan

2018

221. Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, **Pacher P**, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, LePine Pongratz R, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1 α Transactivation in Steatohepatitis. *Cell Metab*. 2018 Feb 6;27(2):339-350
222. Zhou Z, Xu MJ, Cai Y, Wang W, Jiang JX, Varga ZV, Feng D, **Pacher P**, Kunos G, Torok NJ, Gao B. Neutrophil-Hepatic Stellate Cell Interactions Promote Fibrosis in Experimental Steatohepatitis. *Cell Mol Gastroenterol Hepatol*. 2018 Jan 8;5(3):399-413.
223. Csóka B, Németh ZH, Duerr CU, Fritz JH, **PACHER P**, Haskó G. Adenosine receptors differentially regulate type 2 cytokine production by IL-33-activated bone marrow cells, ILC2s, and macrophages. *FASEB J*. 2018 Feb;32(2):829-837.
224. Nagy L, Márton J, Vida A, Kis G, Bokor É, Kun S, Gönczi M, Docsa T, Tóth A, Antal M, Gergely P, Csóka B, **PACHER P**, Somsák L, Bai P. Glycogen phosphorylase inhibition improves beta cell function. *Br J Pharmacol*. 2018 Jan;175(2):301-319.
225. Jourdan T, Park JK, Varga ZV, Pálóczi J, Coffey NJ, Rosenberg AZ, Godlewski G, Cinar R, Mackie K, **PACHER P**, Kunos G. Cannabinoid-1 receptor deletion in podocytes mitigates both glomerular and tubular dysfunction in a mouse model of diabetic nephropathy. *Diabetes Obes Metab*. 2018 Mar;20(3):698-708.
226. Soethoudt M, Stolze SC, Westphal MV, van Stralen L, Martella A, van Rooden EJ, Guba W, Varga ZV, Deng H, van Kasteren SI, Grether U, IJzerman AP, **Pacher P**, Carreira EM, Overkleeft HS, Ioan-Facsinay A, Heitman LH, van der Stelt M. Selective Photoaffinity Probe That Enables Assessment of Cannabinoid CB2 Receptor Expression and Ligand Engagement in Human Cells *J Am Chem Soc*. 2018 May 16;140(19):6067-6075.
227. Chen H, Shen F, Sherban A, Nocon A, Li Y, Wang H, Xu MJ, Rui X, Han J, Jiang B, Lee D, Li N, Keyhani-Nejad F, Fan JG, Liu F, Kamat A, Musi N, Guarente L, **Pacher P**, Gao B, Zang M. DEP domain-containing mTOR-interacting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease. *Hepatology* 2018 Aug;68(2):496-514
228. Varga ZV, Matyas C, Erdelyi K, Cinar R, Nieri D, Chicca A, Nemeth BT, Paloczi J, Lajtos T, Corey L, Hasko G, Gao B, Kunos G, Gertsch J, **PACHER P**. β -Caryophyllene protects against alcoholic steatohepatitis by attenuating inflammation and metabolic dysregulation in mice. *Br J Pharmacol*. 2018 Jan;175(2):320-334.
229. Csóka B, Németh ZH, Szabó I, Davies DL, Varga ZV, Pálóczi J, Falzoni S, Di Virgilio F, Muramatsu R, Yamashita T, **Pacher P**, Haskó G. Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. *JCI Insight*. 2018 Jun 7;3(11). pii: 99431.
230. Valenta I, Varga ZV, Valentine H, Cinar R, Horti A, Mathews WB, Dannals RF, Steele K, Kunos G, Wahl RL, Pomper MG, Wong DF, **Pacher P**, Schindler TH. (Co-corresponding Author) Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach. *JACC Cardiovasc Imaging*. 2018 Feb;11(2 Pt 2):320-332.
231. Varga ZV, Erdelyi K, Paloczi J, Cinar R, Zsengeller ZK, Jourdan T, Matyas C, Balazs NT, Guillot A, Xiang X, Mehal A, Hasko G, Stillman IE, Rosen S, Gao B, Kunos G, **Pacher P**. Disruption of renal arginine metabolism promotes kidney injury in hepatorenal syndrome. *Hepatology* 2018 Oct;68(4):1519-1533.

2019

232. Wang S, Ni HM, Chao X, Wang H, Bridges B, Kumer S, Schmitt T, Mareninova O, Gukovskaya A, De Lisle RC, Ballabio A, **Pacher P**, Ding WX. Impaired TFEB-mediated lysosomal biogenesis promotes the development of pancreatitis in mice and is associated with human pancreatitis. *Autophagy*. 2019 Nov;15(11):1954-1969.
233. Gao Y, Zhou Z, Ren T, Kim SJ, He Y, Seo W, Guillot A, Ding Y, Wu R, Shao S, Wang X, Zhang H, Wang W, Feng D, Xu M, Han E, Zhong W, Zhou Z, **Pacher P**, Niu J, Gao B. Alcohol inhibits T-cell glucose

- metabolism and hepatitis in ALDH2-deficient mice and humans: roles of acetaldehyde and glucocorticoids. *Gut*. 2019 Jul;68(7):1311-1322. doi: 10.1136/gutjnl-2018-316221.
234. Lee JS, Mukhopadhyay P, Matyas C, Trojnar E, Paloczi J, Yang YR, Blank BA, Savage C, Sorokin AV, Mehta NN, Vendruscolo JCM, Koob GF, Vendruscolo LF, **Pacher P**, Lohoff FW. *Sci Rep*. 2019 Nov 20;9(1):17167. doi: 10.1038/s41598-019-53603-6.(Co corresponding author)
235. Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, Matyas C, Mo R, Shang D, He Y, Seo W, Shah VH, **Pacher P**, Xie Q, Gao B. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming of impaired regeneration pathways in mice. *J Hepatol*. 2019 Nov 28. pii: S0168-8278(19)30700-7. doi: 10.1016/j.jhep.2019.11.013. [Epub ahead of print]
236. Paloczi J, Matyas C, Cinar R, Varga ZV, Hasko G, Schindler TH, Kunos G, **Pacher P**. Alcohol Binge-Induced Cardiovascular Dysfunction Involves Endocannabinoid-CB1-R Signaling. *JACC Basic Transl Sci*. 2019 Sep 23;4(5):625-637. doi: 10.1016/j.jacbts.2019.05.007. (Editorial highlight)
- 2020**
237. Wang S, Ni HM, Chao X, Ma X, Kolodecik T, De Lisle R, Ballabio A, **Pacher P**, Ding WX. Critical Role of TFEB-Mediated Lysosomal Biogenesis in Alcohol-Induced Pancreatitis in Mice and Humans. *Cell Mol Gastroenterol Hepatol*. 2020;10(1):59-81.
238. Xiang X, Feng D, Hwang S, Ren T, Wang X, Trojnar E, Matyas C, Mo R, Shang D, He Y, Seo W, Shah VH, **Pacher P**, Xie Q, Gao B. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. *J Hepatol*. 2020 Apr;72(4):736-745.
239. Haider A, Gobbi L, Kretz J, Ullmer C, Brink A, Honer M, Woltering TJ, Muri D, Iding H, Bürkler M, Binder M, Bartelmus C, Knuesel I, **Pacher P**, Herde AM, Spinelli F, Ahmed H, Atz K, Keller C, Weber M, Schibli R, Mu L, Grether U, Ametamey SM. Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. *J Med Chem*. 2020 Sep 1. doi: 10.1021/acs.jmedchem.0c00778. Online ahead of print.
240. Trojnar E, Erdelyi K, Matyas C, Zhao S, Paloczi J, Mukhopadhyay P, Varga ZV, Hasko G, **Pacher P**. Cannabinoid-2 receptor activation ameliorates hepatorenal syndrome. *Free Radic Biol Med*. 2020 May 20;152:540-550
241. van Esbroeck ACM, Varga ZV, Di X, van Rooden EJ, Tóth VE, Onódi Z, Kuśmierczyk M, Leszek P, Ferdinandy P, Hankemeier T, van der Stelt M, **Pacher P**. Activity-based protein profiling of the human failing ischemic heart reveals alterations in hydrolase activities involving the endocannabinoid system. *Pharmacol Res*. 2020 Jan;151:104578. doi: 10.1016/j.phrs.2019.104578.
242. Matyas C, Erdelyi K, Trojnar E, Zhao S, Varga ZV, Paloczi J, Mukhopadhyay P, Nemeth BT, Haskó G, Cinar R, Rodrigues RM, Ait Ahmed Y, Gao B, **Pacher P**. Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy. *Hepatology*. 2020 Apr;71(4):1391-1407 (Cover Highlight)
243. Sarott RC, Westphal M, Pfaff P, Korn C, Sykes DA, Gazzi T, Brennecke B, Atz K, Weise M, Mostinski Y, Hompluem P, Koers E, Miljus T, Roth NJ, Asmelash H, Vong MC, Piovesan J, Guba W, Rufer A, Kuszniir EA, Huber S, Raposo C, Zirwes EA, Osterwald A, Pavlovic A, Moes S, Beck J, Benito-Cuesta I, Grande T, Ruiz de Martin S, Yeliseev AA, Drawnel F, Widmer G, Holzer D, van der Wel T, Mandhair H, Yuan CY, Drobyski W, Saroz Y, Grimsey NL, Honer M, Fingerle J, Gawrisch K, Romero J, Hillard C, Varga Z, van der Stelt M, **Pacher P**, Gertsch J, McCormick P, Ullmer C, Oddi S, Maccarrone M, Veprintsev D, Nazaré M, Grether U, Carreira EM. Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells. *J Am Chem Soc*. 2020 Oct 7;142(40):16953-16964. doi: 10.1021/jacs.0c05587.
244. Mock ED, Mustafa M, Gunduz-Cinar O, Cinar R, Petrie GN, Kantae V, Di X, Ogasawara D, Varga ZV, Paloczi J, Miliano C, Donvito G, van Esbroeck ACM, van der Gracht AMF, Kotsogianni I, Park JK, Martella A, van der Wel T, Soethoudt M, Jiang M, Wendel TJ, Janssen APA, Bakker AT, Donovan CM, Castillo LI, Florea BI, Wat J, van den Hurk H, Wittwer M, Grether U, Holmes A, van Boeckel CAA, Hankemeier T, Cravatt BF, Buczynski MW, Hill MN, **Pacher P**, Lichtman AH, van der Stelt M. Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice. *Nat Chem Biol*. 2020 Jun;16(6):667-675. doi: 10.1038/s41589-020-0528-7.
- 2021**
245. He Y, Rodrigues RM, Wang X, Seo W, Ma J, Hwang S, Fu Y, Trojnar E, Mátyás C, Zhao S, Ren R, Feng D, **Pacher P**, Kunos G, Gao B. Neutrophil-to-hepatocyte communication via LDLR-dependent miR-223-enriched extracellular vesicle transfer ameliorates nonalcoholic steatohepatitis. *J Clin Invest*. 2021 Feb 1;131(3):e141513. doi: 10.1172/JCI141513.
246. Lovászi M, Németh ZH, Gause WC, Beesley J, **Pacher P**, Haskó G. Inosine monophosphate and inosine differentially regulate endotoxemia and bacterial sepsis. *FASEB J*. 2021 Nov;35(11):e21935. doi: 10.1096/fj.202100862R.
247. Haas CB, Lovászi M, **Pacher P**, de Souza PO, Pelletier J, Leite RO, Sévigny J, Németh Z, Braganhol E, Haskó G. Extracellular ectonucleotidases are differentially regulated in murine tissues and human polymorphonuclear leukocytes during sepsis and inflammation. *Purinergic Signal*. 2021 Dec;17(4):713-724. doi: 10.1007/s11302-021-09819-1.

248. Guillot A, Guerri L, Feng D, Kim SJ, Ahmed YA, Paloczi J, He Y, Schuebel K, Dai S, Liu F, **Pacher P**, Kisseleva T, Qin X, Goldman D, Tacke F, Gao B. Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin $\alpha\beta6$ upregulation following liver injury. *J Clin Invest*. 2021 May 3;131(9):e132305. doi: 10.1172/JCI132305.

2022

249. Wang S, Chao X, Jiang X, Wang T, Rodriguez Y, Yang L, **Pacher P**, Ni HM, Ding WX. Loss of acinar cell VMP1 triggers spontaneous pancreatitis in mice. *Autophagy*. 2022 Jul;18(7):1572-1582. doi: 10.1080/15548627.2021.1990672.
250. Abraham S, Lindo C, Peoples J, Cox A, Lytle E, Nguyen V, Mehta M, Alvarez JD, Yooseph S, Pacher P, Ebert SN. Maternal binge alcohol consumption leads to distinctive acute perturbations in embryonic cardiac gene expression profiles. *Alcohol Clin Exp Res*. 2022 Aug;46(8):1433-1448. doi: 10.1111/acer.14880.
251. Gazzi T, Brennecke B, Atz K, Korn C, Sykes D, Forn-Cuni G, Pfaff P, Sarott RC, Westphal MV, Mostinski Y, Mach L, Wasinska-Kalwa M, Weise M, Hoare BL, Miljuš T, Mexi M, Roth N, Koers EJ, Guba W, Alker A, Rufer AC, Kuznir EA, Huber S, Raposo C, Zirwes EA, Osterwald A, Pavlovic A, Moes S, Beck J, Nettekoven M, Benito-Cuesta I, Grande T, Drawnel F, Widmer G, Holzer D, van der Wel T, Mandhair H, Honer M, Fingerle J, Scheffel J, Broichhagen J, Gawrisch K, Romero J, Hillard CJ, Varga ZV, van der Stelt M, **Pacher P**, Gertsch J, Ullmer C, McCormick PJ, Oddi S, Spaink HP, Maccarrone M, Veprintsev DB, Carreira EM, Grether U, Nazaré M. Detection of cannabinoid receptor type 2 in native cells and zebrafish with a highly potent, cell-permeable fluorescent probe. *Chem Sci*. 2022 Apr 1;13(19):5539-5545. doi: 10.1039/d1sc06659e.
252. Lovász M, Németh ZH, **Pacher P**, Gause WC, Wagener G, Haskó G. A2A adenosine receptor activation prevents neutrophil aging and promotes polarization from N1 towards N2 phenotype. *Purinergic Signal*. 2022 Sep;18(3):345-358. doi: 10.1007/s11302-022-09884-0.
253. Kelestemur T, Németh ZH, **Pacher P**, Antonioli L, Haskó G. A 2A ADENOSINE RECEPTORS REGULATE MULTIPLE ORGAN FAILURE AFTER HEMORRHAGIC SHOCK IN MICE. *Shock*. 2022 Oct 1;58(4):321-331. doi: 10.1097/SHK.0000000000001985.
254. Rajesh M, Mukhopadhyay P, Bátkai S, Arif M, Varga ZV, Mátyás C, Paloczi J, Lehocki A, Haskó G, **Pacher P**. Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis. *Geroscience*. 2022 Jun;44(3):1727-1741. doi: 10.1007/s11357-022-00565-9. (Highlighted publication by NIH IPR)

2023

255. Cinato M, Mardani I, Miljanovic A, Drevinge C, Laudette M, Bollano E, Henriksen M, Toló J, Bauza Thorbrügge M, Levin M, Lindbom M, Arif M, **Pacher P**, Andersson L, Olofsson CS, Borén J, Levin MC. Cardiac Plin5 interacts with SERCA2 and promotes calcium handling and cardiomyocyte contractility. *Life Sci Alliance*. 2023 Jan 30;6(4):e202201690. doi: 10.26508/lsa.202201690.
256. Kelestemur T, Németh ZH, **Pacher P**, Beesley J, Robson SC, Eltzschig HK, Haskó G. Adenosine metabolized from extracellular ATP ameliorates organ injury by triggering A2BR signaling. *Respir Res*. 2023 Jul 13;24(1):186. doi: 10.1186/s12931-023-02486-3.
257. Sayour NV, Tóth VÉ, Nagy RN, Vörös I, Gergely TG, Onódi Z, Nagy N, Bödör C, Váradi B, Ruppert M, Radovits T, Bleckwedel F, Zelarayán LC, **Pacher P**, Ágg B, Görbe A, Ferdinandy P, Varga ZV. Droplet Digital PCR Is a Novel Screening Method Identifying Potential Cardiac G-Protein-Coupled Receptors as Candidate Pharmacological Targets in a Rat Model of Pressure-Overload-Induced Cardiac Dysfunction. *Int J Mol Sci*. 2023 Sep 7;24(18):13826. doi: 10.3390/ijms241813826.
258. Gulej R, Nyúl-Tóth Á, Ahire C, DelFavero J, Balasubramanian P, Kiss T, Tarantini S, Benyo Z, **Pacher P**, Csik B, Yabluchanskiy A, Mukli P, Kuan-Celarié A, Krizbai IA, Campisi J, Sonntag WE, Csiszar A, Ungvari Z. Elimination of senescent cells by treatment with Navitoclax/ABT263 reverses whole brain irradiation-induced blood-brain barrier disruption in the mouse brain. *Geroscience*. 2023 Oct;45(5):2983-3002. doi: 10.1007/s11357-023-00870-x.
259. Arif M, Matyas C, Mukhopadhyay P, Yokus B, Trojnar E, Paloczi J, Paes-Leme B, Zhao S, Lohoff FW, Haskó G, **Pacher P**. Data-driven transcriptomics analysis identifies PCSK9 as a novel key regulator in liver aging. *Geroscience*. 2023 Oct;45(5):3059-3077. doi: 10.1007/s11357-023-00928-w. (Editorial highlight)
260. Jiang M, Huizenga MCW, Wirt JL, Paloczi J, Amedi A, van den Berg RJBHN, Benz J, Collin L, Deng H, Di X, Driever WF, Florea BI, Grether U, Janssen APA, Hankemeier T, Heitman LH, Lam TW, Mohr F, Pavlovic A, Ruf I, van den Hurk H, Stevens AF, van der Vliet D, van der Wel T, Wittwer MB, van Boeckel CAA, **Pacher P**, Hohmann AG, van der Stelt M. A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence. *Nat Commun*. 2023 Dec 5;14(1):8039. doi: 10.1038/s41467-023-43606-3.
261. Li X, Chang H, Bouma J, de Paus LV, Mukhopadhyay P, Paloczi J, Mustafa M, van der Horst C, Kumar SS, Wu L, Yu Y, van den Berg RJBHN, Janssen APA, Lichtman A, Liu ZJ, **Pacher P**, van der Stelt M, Heitman LH, Hua T. Structural basis of selective cannabinoid CB2 receptor activation. *Nat Commun*. 2023 Mar 15;14(1):1447. doi: 10.1038/s41467-023-37112-9. (Co-corresponding Author)

262. Matyas C, Trojnar E, Zhao S, Arif M, Mukhopadhyay P, Kovacs A, Fabian A, Tokodi M, Bagyura Z, Merkely B, Kohidai L, Lajko E, Takacs A, He Y, Gao B, Paloczi J, Lohoff FW, Haskó G, Ding WX, **Pacher P**. PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction. *JACC Basic Transl Sci*. 2023 Sep 13;8(10):1334-1353. doi: 10.1016/j.jacbts.2023.06.005.(Editorial highlight)

2024

263. Lovászi M, Németh ZH, Kelestemur T, Sánchez IV, Antonioli L, **Pacher P**, Wagener G, Haskó G. EVALUATION OF COMPONENTS OF THE EXTRACELLULAR PURINERGIC SIGNALING SYSTEM IN HUMAN SEPSIS. *Shock*. 2024 Apr 1;61(4):527-540. doi: 10.1097/SHK.0000000000002230.
264. Kucsera D, Ruppert M, Sayour NV, Tóth VE, Kovács T, Hegedűs ZI, Onódi Z, Fábíán A, Kovács A, Radovits T, Merkely B, **Pacher P**, Ferdinandy P, Varga ZV. NASH triggers cardiometabolic HFpEF in aging mice. *Geroscience*. 2024 Apr 17. doi: 10.1007/s11357-024-01153-9.
265. Rosoff DB, Bell AS, Mavromatis LA, Hamandi A, Park L, Jung J, Wagner J, **Pacher P**, Ray D, Davey Smith G, Lohoff FW. Evaluating the Cardiovascular Impact of Genetically Proxied PCSK9 and HMGCR Inhibition in East Asian and European Populations: A Drug-Target Mendelian Randomization Study. *Circ Genom Precis Med*. 2024 Feb;17(1):e004224. doi: 10.1161/CIRCGEN.122.004224.
266. Wagner J, Park LM, Mukhopadhyay P, Matyas C, Trojnar E, Damadzic R, Jung J, Bell AS, Mavromatis LA, Hamandi AM, Rosoff DB, Vendruscolo LF, Koob GF, **Pacher P**, Lohoff FW. PCSK9 inhibition attenuates alcohol-associated neuronal oxidative stress and cellular injury. *Brain Behav Immun*. 2024 Apr 22;119:494-506. doi: 10.1016/j.bbi.2024.04.022.
267. Y Fu, B Mackowiak, Y Lin, L Maccioni, T Lehner, H Pan, Y Guan, G Godlewski, H Lu, C Chen, S Wei, D Feng, J Paloczi, H Zhou, **P Pacher**, L Zhang, G Kunos, B Gao. Coordinated action of a gut-liver pathway drives 3 alcohol detoxification and consumption. *Nature Metabolism* 2024 in press.
268. Chicca A, Batora, D, Ullmer C, Caruso A, Grüner S, Fingerle J, Hartung T, Degen R, Müller M, Grether, U, **Pacher P**, Gertsch J. A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for in vivo studies *ACS Pharmacology & Translational Science under review* (Co-corresponding Author)

PEER-REVIEWED INVITED REVIEW PAPERS

1998-2003

269. **P PACHER**, Z Ungvári, V Kecskeméti, S Fürst. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. *Current Med Chemistry* 1998; 5, 381-390.
270. **P PACHER**, Z Ungvári, P P Nánási, S Fürst, V Kecskeméti. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? *Curr Med Chem*. 1999; 6, 469-480.
271. **P PACHER**, E Köhegyi, V Kecskeméti, S Fürst. Current trends in the development of new antidepressants. *Current Med Chemistry*. 2001;8:89-100.
272. **P PACHER**, G Csordás & G Hajnoczky. Mitochondrial Ca²⁺ signaling in cardiac apoptosis. *Biological Signals and Receptors (Neurosignals)*. 2001; 10(3-4):200-223.
273. G Hajnoczky, **P PACHER**, X Lin. Spatio-temporal organization of the mitochondrial phase of apoptosis. 2001. *IUBMB Life* 2001; 52:237-245.
274. G Hajnoczky, G Csordas, M Madesh, **P Pacher**. Control of apoptosis by IP3 and ryanodine receptor driven calcium signals. *Cell Calcium* 2000; 28, 1-15.
275. G Hajnoczky, G Csordas, M Madesh, **P PACHER**. The machinery of local Ca²⁺ signaling between sarco-endoplasmic reticulum and mitochondria. *J Physiol (London)* 2000;529:69-81.
276. **P PACHER** & Z Ungvari. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly by inhibiting cardiovascular ion channels. *Medical Hypotheses* 2001; 57(4):469-71.
277. L Liaudet, A Deb, **P PACHER**, JG. Mabley, KGK. Murthy, AL. Salzman and Szabó. The Flagellin- TLR5 Axis: Therapeutic Opportunities. *Drug News & Perspectives* 2002 Sep;15(7):397-409.
278. V Kecskeméti, Z Bagi, **P PACHER**, I Posa, Kocsis E, Koltai MZ. New trends in the development of oral antidiabetic drugs. *Current Med Chemistry* 2002; 1:53-71.

2004-2005

279. **P PACHER**, V Kecskeméti. Trends in the development of antidepressants: is there a light at the end of the tunnel? *Curr Med Chem* 2004; 7:925-943.
280. **P PACHER**, V Kecskeméti. Cardiovascular effects of new antidepressants and antipsychotics. *Current Pharmaceutical Design* 2004;10(20):2463-2475.
281. G Hajnoczky, CJ Buzas, **P PACHER**, JB Hoek and E Rubin. Alcohol and mitochondria in cardiac apoptosis: mechanisms and visualization *Alcohol Clin Exp Res* 2005;29(5):693-701.
282. A Csiszar, **P PACHER**, G Kaley, Z Ungvari Role of oxidative and nitrosative stress, longevity genes and

Pal Pacher M.D., Ph.D. - CV

- poly(ADP-ribose) polymerase in cardiovascular dysfunction associated with aging. *Curr Vasc Pharmacol* **2005** July, 3(3) 285-293.
283. M Begg, **P PACHER**, S Bátkai, D Osei-Hyiaman, L Offertáler, FM Mo, J Liu and G Kunos. Evidence for novel cannabinoid receptors. *Pharmacol Therap* **2005** May;106(2):133-145.
284. G Haskó, **P PACHER**, ES Vizi, P Illes. Adenosine receptor signaling in the brain immune system. *Trends Pharmacol Sci* **2005** Oct;26(10):511-516.
285. Z Ungvári, SA Gupte, FA Recchia, S Bátkai and **P PACHER**. Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. *Curr Vasc Pharmacol* **2005** July, 3(3) 221-231. (**Cover highlight**).
286. **P PACHER**, S Batakai, G Kunos. Blood pressure regulation by endocannabinoids and their receptors. *Neuropharm* **2005** Jun;48(8):1130-1138.
287. **P PACHER** & C Szabó Role of poly(ADP-ribose) polymerase-1 (PARP) activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. *Antiox Redox Signal* **2005** Nov-Dec;7(11-12):1568-80.
288. **P PACHER**, I Obrosova, JG Mabley & C Szabó Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutic strategies *Curr Med Chem* **2005**;12(3):267-275.
289. **P PACHER**, R Shultz, L Liaudet, C Szabo. Nitrosative stress and pharmacological modulation of heart failure. *Trends Pharmacol Sci* **2005** Jun;26(6):302-310.
- 2006**
290. O Evgenov, **P PACHER**, PM Schmidt, G Hasko, HW Schmidt, J-P Stasch. Nitric-oxide independent stimulators of soluble guanylate cyclase: Development and therapeutic potential. *Nature Reviews Drug Discovery* **2006** Sep;5(9):755-768.
291. C Szabo, **P PACHER**, RA Swanson. Novel modulators of poly(ADP)polymerase. *Trends Pharmacol Sci* **2006** Dec; 27(12):626-630.
292. **P PACHER**, C Szabo. Role of Peroxynitrite in the Pathogenesis of Cardiovascular Complications of Diabetes. *Curr Op Pharmacol* **2006** Apr;6(2):136-41.
293. **P PACHER**, A Nivorozhkin, C Szabo. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. *Pharmacological Reviews* **2006** March 58:87-114.
294. **P PACHER**, S Batakai, G Kunos. The endocannabinoid system as an emerging target for pharmacotherapy. *Pharmacological Reviews* **2006**; Sept; 58(3): 389-462 (**ISI: fast breaking paper in pharmacology, highly cited**).
- 2007**
295. G Hasko, **P PACHER**, EA Deitch, and ES Vizi. Shaping of monocyte and macrophage function by adenosine receptors. *Pharmacol Therap* **2007** Feb;113(2):264-75.
296. **P PACHER** and C Szabo. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. *Cardiovasc Drug Rev.* 2007 Fall;25(3):235-60.
297. **P PACHER**, L Liaudet, JS Beckman. Nitric oxide and peroxynitrite in health and disease. *Physiological Reviews* 2007; 87:315-424. (**Cover highlight; ISI:hot paper/highly cited in biochemistry/biology**).
- 2008**
298. Z Selmeczy, ES Vizi, B Csóka, **P PACHER**, G Haskó. Role of nonsynaptic communication in regulating the immune response. *Neurochem Int.* 2008 Jan;52(1-2):52-9.
299. Haskó G, **PACHER P**. A2A receptors in inflammation and injury: lessons learned from transgenic animals. *J Leukoc Biol.* 2008 Mar;83(3):447-55.
300. **P PACHER**, B Gao. Endocannabinoid Effects on Immune Cells: Implications for Inflammatory Liver Diseases. *Am J Physiol Gastrointest Liver Physiol.* 2008 Apr;294(4):G850-4.
301. **PACHER P**, Haskó G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. *Br J Pharmacol.* 2008 Jan;153(2):252-62.
302. **P PACHER**, P Mukhopadhyay, M Rajesh, S Bátkai, G Kunos. Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential. *Hypertension* 2008 Oct;52(4):601-7
303. **P PACHER**, C Szabo. Role of peroxynitrite and PARP in human diseases. *Am J Pathology.* 2008 Jul;173(1):2-13.
304. G Hasko, J Linden, B Cronstein, **P PACHER**. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nature Reviews Drug Discovery* 2008 Sep;7(9):759-70.
- 2009**
305. **P PACHER**, S Steffens. The emerging role of the endocannabinoid system in cardiovascular disease. *Semin Immunopathol.* 2009 Jun;31(1):63-77.
306. S Batakai, **P PACHER**. Endocannabinoids and Cardiac Contractile Function: Pathophysiological Implications. *Pharmacological Research* 2009 Aug;60(2):99-106.
307. L Liaudet, G Vassalli, **P PACHER**. Role of peroxynitrite in the redox regulation of cell signal transduction pathways. *Front Biosci.* 2009 Jan 1;14:4809-14.
308. T Biro, BI Toth, G Hasko, R Paus, **P PACHER** . The endocannabinoid system of the skin in health and

- disease: novel perspectives and therapeutic opportunities. *Trends Pharmacol Sci* 2009;30(8):411-20.
309. G Hasko, B Csoka, ZH Nemeth, ES Vizi, and **P PACHER**. A_{2B} adenosine receptors in immunity and inflammation. *Trends Immunol* 2009 Jun;30(6):263-70.

2011

310. B Kocso, B Csoka, **P PACHER**, G Hasko. Investigational A₃ adenosine receptor targeting agents. *Curr Op Investig Drugs* 2011; 20(6):757-68.
311. J-P Stasch, **PACHER P**, Evgenov O. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary diseases. *Circulation* 2011; 123(20):2263-73. (co-corresponding author).
312. **P PACHER**, R Mechoulam. Is lipid signaling through cannabinoid 2 receptors part of a protective system? *Progress in Lipid Research* 2011 Feb 2;50(2):193-211.

2012

313. B Horvath, P Mukhopadhyay, G Hasko, **P PACHER**. The endocannabinoid system: plant-derived cannabinoids in diabetes and diabetic complications. *Am J Pathology* 2012 Feb;180(2):432-42.
314. G Hasko, **P PACHER**. Regulation of macrophage function by adenosine. *Arterioscler Thromb Vasc Biol*. 2012 Apr;32(4):865-9.

2013

315. L Liaudet, N Rosenblatt-Velin, **P PACHER**. Role of peroxynitrite in the cardiovascular dysfunction of septic shock. *Curr Vasc Pharmacol* 2013 Mar 1;11(2):196-207.
316. S Steffens, **P PACHER**. Targeting cannabinoid receptor CB₂ in cardiovascular disorders: promises and controversies. *Br J Pharmacol*. 2013 Jan;168(1):76-8.
317. Antonioli L, **PACHER**, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. *Trends Mol Med*. 2013 Jun;19(6):355-67.
318. Antonioli L, Blandizzi C, **PACHER P**, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. *Nat Rev Cancer*. 2013 Dec;13(12):842-57.
319. **PACHER P**, Kunos G. Modulating the endocannabinoid system in human health and disease--successes and failures. *FEBS J*. 2013 May;280(9):1918-43. Most highly cited paper in journal in 2015 since 2013.

2014

320. Liaudet L, Calderari B, **PACHER P**. Pathophysiological mechanisms of catecholamine and cocaine-mediated cardiotoxicity. *Heart Fail Rev*. 2014 Nov;19(6):815-24.
321. Varga ZV, Giricz Z, Liaudet L, Haskó G, Ferdinandy P, **PACHER P**. Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy. *BBA Mol Mech Dis* 2015 Feb;1852(2):232-242.

2015

322. Pechánová O, Varga ZV, Cebová M, Giricz Z, **PACHER P**, Ferdinandy P. Cardiac NO signalling in the metabolic syndrome. *Br J Pharmacol*. 2015 Mar;172(6):1415-33. doi: 10.1111/bph.12960.
323. Steffens S, **PACHER P**. The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism? *Curr Drug Targets*. 2015;16(4):334-41.
324. Maccarrone M, Bab I, Bíró T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, **PACHER P**, Sharkey KA, Zimmer A. Endocannabinoid signaling at the periphery: 50 years after THC. *Trends Pharmacol Sci*. 2015 May;36(5):277-96. doi: 10.1016/j.tips.2015.02.008.
325. Antonioli L, Blandizzi C, Csoka B, **PACHER P**, Hasko G. Adenosine signaling in diabetes mellitus-pathophysiology and therapeutic considerations. *Nature Reviews Endocrinology* 2015 Apr;11(4):228- 41. doi: 10.1038/nrendo.2015.10.
326. Bai P, Nagy L, Fodor T, Liaudet L, **PACHER P**. Poly(ADP-ribose) polymerases as modulators of mitochondrial activity. *Trends Endocrinol Metab* 2015 Feb;26(2):75-83.

2016

327. Wang S, **PACHER P**, De Lisle RC, Huang H, Ding WX. A Mechanistic Review of Cell Death in Alcohol-Induced Liver Injury. *Alcohol Clin Exp Res*. 2016 Jun;40(6):1215-23. doi: 10.1111/acer.13078. PMID: 27130888
328. Antonioli L, Yegutkin GG, **PACHER P**, Blandizzi C, Haskó G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. *Trends Cancer*. 2016 Feb 1;2(2):95-109.
329. Varga ZV, Ferdinandy P, Liaudet L, **PACHER P**. Drug-induced mitochondrial dysfunction and cardiotoxicity. *Am J Physiol Heart Circ Physiol*. 2015 Nov;309(9):H1453-67
330. Varga ZV, Matyas C, Paloczi J, **PACHER P**. Alcohol Misuse and Kidney Injury: Epidemiological Evidence and Potential Mechanisms. *Alcohol Research: Current Reviews* inpress
331. Gruden G, Barutta F, Kunos G, **PACHER P**. Role of the Endocannabinoid System in Diabetes and Diabetic Complications. *Br J. Pharmacol* 2015 Jun 16. doi: 10.1111/bph.13226. [Epub ahead of print]
332. Benyó Z, Ruisanchez É, Leszl-Ishiguro M, Sándor P, **PACHER P**. Endocannabinoids in Cerebrovascular Regulation. *Am J Physiol Heart Circ Physiol*. 2016 Apr 1;310(7):H785-801. doi: 10.1152/ajpheart.00571.2015.

2017

333. Varga ZV, Matyas C, Paloczi J, **Pacher P**. Alcohol Misuse and Kidney Injury: Epidemiological Evidence and Potential Mechanisms. *Alcohol Res*. 2017;38(2):283-288. Review.
334. Nemeth BT, Varga ZV, Wu WJ, **PACHER P**. Trastuzumab cardiotoxicity: from clinical trials to experimental studies. *Br J Pharmacol*. **Br J Pharmacol**. 2017 Nov;174(21):3727-3748.
- 2018**
335. Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, **PACHER P**, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegei B, Swanson RA, Szabo C. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. *Br J Pharmacol*. 2018 Jan;175(2):192-222.
336. Paloczi J, Varga ZV, Haskó G, **PACHER P**. Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation. *Antioxid Redox Signal*. 2018 Jul 1;29(1):75-108.
337. Ungvari Z, Tarantini S, Kiss T, Wren JD, Giles CB, Griffin CT, Murfee WL, **Pacher P**, Csiszar A. Endothelial dysfunction, and angiogenesis impairment in the ageing vasculature. *Nat Rev Cardiol*. 2018 Sep;15(9):555-565.
338. Antonioli L, Blandizzi C, **Pacher P**, Williams M, Haskó G. Quorum sensing in the immune system. *Nat Rev Immunol*. 2018 Sep;18(9):537-538. doi: 10.1038/s41577-018-0040-4.
339. **PACHER P**, Steffens S, Haskó G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. *Nat Rev Cardiol*. 2018 Mar;15(3):151-166 (#2 hottest paper in Nat Reviews Cardiology)
- 2019**
340. Antonioli L, Blandizzi C, **Pacher P**, Williams M, Haskó G. Rethinking Communication in the Immune System: The Quorum Sensing Concept. *Trends Immunol*. 2019 Feb;40(2):88-97. doi: 10.1016/j.it.2018.12.002.
341. Antonioli L, Fornai M, Blandizzi C, **Pacher P**, Haskó G. Adenosine signaling and the immune system: When a lot could be too much. *Immunol Lett*. 2019 Jan; 205:9-15.
342. Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, **Pacher P**, Varga ZV, Varró A, Schulz R. Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. *Eur Heart J*. 2019 Jun 7;40(22):1771-1777. doi: 10.1093/eurheartj/ehy365.
343. Valenta I, **Pacher P**, Dilsizian V, Schindler TH. Novel Myocardial PET/CT Receptor Imaging and Potential Therapeutic Targets. *Curr Cardiol Rep*. 2019 May 18;21(7):55. doi: 10.1007/s11886-019-1148-2.
344. Antonioli L, Blandizzi C, Fornai M, **Pacher P**, Lee HT, Haskó G. P2X4 receptors, immunity, and sepsis. *Curr Opin Pharmacol*. 2019 Aug; 47:65-74. doi: 10.1016/j.coph.2019.02.011.
345. Antonioli L, Blandizzi C, **Pacher P**, Haskó G. The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases. *Pharmacol Rev*. 2019 Jul;71(3):345-382.
- 2020**
346. Rehman A, Baloch NU, Morrow JP, **Pacher P**, Haskó G. Targeting of G-protein coupled receptors in sepsis. *Pharmacol Ther* 2020 Jul; 211:107529 doi: 10.1016/j.pharmthera.2020.107529 in press
347. **Pacher P**, Kogan NM, Mechoulam R. Beyond THC and Endocannabinoids. *Annu Rev Pharmacol Toxicol*. 2020 Jan 6; 60:637-659.
- 2021**
348. Lovászi M, Branco Haas C, Antonioli L, **Pacher P**, Haskó G. The role of P2Y receptors in regulating immunity and metabolism. *Biochem Pharmacol*. 2021 Jan 15:114419. doi: 10.1016/j.bcp.2021.114419
349. Rehman A, **Pacher P**, Haskó G. Role of Macrophages in the Endocrine System. *Trends Endocrinol Metab*. 2021 Apr;32(4):238-256. doi: 10.1016/j.tem.2020.12.001.
350. Haas CB, Lovászi M, Braganhol E, **Pacher P**, Haskó G. Ectonucleotidases in Inflammation, Immunity, and Cancer. *J Immunol*. 2021 May 1;206(9):1983-1990. doi: 10.4049/jimmunol.2001342.
351. Lee JS, O'Connell EM, **Pacher P**, Lohoff FW. PCSK9 and the Gut-Liver-Brain Axis: A Novel Therapeutic Target for Immune Regulation in Alcohol Use Disorder. *J Clin Med*. 2021 Apr 18;10(8):1758. doi: 10.3390/jcm10081758.
352. Szántó WL, Gupte R, Kraus WL, **Pacher P**, Bai P. PARPs in lipid metabolism and related diseases. *Prog Lipid Res*. 2021 Nov;84:101117. doi: 10.1016/j.plipres.2021.101117 (Co-corresponding Author)
353. **Pacher P**. Cyanide emerges as an endogenous mammalian gasotransmitter. *Proc Natl Acad Sci U S A*. 2021 Jun 22;118(25): e2108040118. doi: 10.1073/pnas.2108040118.
354. Matyas C, Trojnar E, Liaudet L, Haskó G, **Pacher P**. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications. *Nat Rev Cardiol*. 2021 Feb;18(2):117-135. doi: 10.1038/s41569-020-0433-5.
- 2022-2024**
355. Antonioli L, **Pacher P**, Haskó G. Adenosine and inflammation: it's time to (re)solve the problem *Trends Pharmacol Sci*. 2022 Jan;43(1):43-55. doi: 10.1016/j.tips.2021.10. 010.

Pal Pacher M.D., Ph.D. - CV

356. Antonioli L, Fornai M, Pellegrini C, **Pacher P**, Haskó G. Adenosine signaling as target in cardiovascular pharmacology. *Curr Opin Pharmacol*. 2023 Aug;71:102393. doi: 10.1016/j.coph.2023.102393.
357. CE Bradley, E Fletcher, T Wilkinson, A Ring, LC Ferrer, D Miserlis, **P Pacher**, P Koutakis. Mitochondrial fatty acid beta-oxidation: a possible therapeutic target for skeletal muscle lipotoxicity in peripheral artery disease myopathy. 2024 *EXCLI Journal*, 23, 523–533. <https://doi.org/10.17179/excli2024-7004>
358. M Kosar, L Mach, EM. Carreira, M Nazaré, **P Pacher**, and U Grether. Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present). *Expert Opinion on Therapeutic Patents* 2024 in press
359. LM. Park, P Pacher, FW.Lohoff. Targeting Oxidative Stress in Neurodegenerative Disorders: A Novel Role for PCSK9 Inhibition? *ACS Viewpoint under review*

INVITED EDITORIALS

2004-2010

360. GKunos, **P PACHER**. Cannabinoids cool the intestine *Nature Medicine* 2004;10(7):678-9.
361. G Kunos, S Batkai, **P PACHER**, JA Wagner. Cannabinoids and endotoxemia. *Am J Physiol Heart Circ Physiol* 288:451-452, 2005.
362. **P PACHER**, S Batkai, G Kunos. Cirrhotic cardiomyopathy: an endocannabinoid connection? *Br J Pharmacol*. 2005 Oct;146(3):313-4.
363. **P PACHER**, ZI Ungvari. Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases. *Am J Physiol Heart Circ Physiol*. 2008 Mar;294(3):H1133-4.
364. **P PACHER**. The endocannabinoid system and cardiovascular disease. *Cardiometabolic Risk Journal*. December 2008 (Vol. 1, Issue 3, pages 41-44).
365. **P PACHER**. Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: A commentary on "PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy" *Free Radic Biol Med*. 2008 Mar 15;44(6):969-71.
366. **P PACHER**. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? *Arterioscler Thromb Vasc Biol*. 2009 Jan;29(1):7-9.
367. G Hasko, **P PACHER**. Endothelial Nrf2 activation: a new target for resveratrol? *Am J Physiol Heart Circ Physiol*. 2010 Jul;299(1):H10-2.

2011-2020

368. G Hasko, **P PACHER**. Suppression of tumorigenicity 2: A Janus-faced player in sepsis. *American Journal of Respiratory and Critical Care Medicine Blue* 2011 Apr 1;183(7):841-3.
369. Editorial Podcast on *Am J Physiol Heart Circ Physiol*. 2011 Nov;301(5):H1907-15. Alignment of sarcoplasmic reticulum-mitochondrial junctions with mitochondrial contact points.
370. **P PACHER**. Editorial on: Distinct regulation of nNOS and iNOS by CB2 receptor in remote delayed neurodegeneration. *J Mol Med* 2012 Apr;90(4):347-51.
371. C Szabo, **P PACHER**. The outsiders: emerging roles of ectonucleotidases in inflammation. *Science Translational Medicine* 2012;4(146):146ps14
372. **P PACHER**. Towards the use of non-psychoactive cannabinoids for prostate cancer. *Br J Pharmacol*. 2013 Jan;168(1):76-8.
373. Csóka B, **PACHER P**, Bai P, Haskó G. New Piece in the Jigsaw Puzzle: Adipose Tissue-Derived Stem Cells From Obese Subjects Drive Th17 Polarization. *Diabetes*. 2015 Jul;64(7):2341-3. doi: 10.2337/db15-0437.
374. Shindler T, **PACHER P**. Psoriasis related Visceral Adiposity and Arterial Inflammation: A New Adiposity Disease Entity? *JACC Cardiovascular Imaging* 2018 Feb;11(2 Pt 2):358-360.
375. Ungvari Z, Yabluchanskiy A, Hasko G, **Pacher P**. Age-dependent cardiovascular effects of sepsis in a murine model of cecal ligation and puncture: implications for the design of interventional studies. *Am J Physiol Heart Circ Physiol*. 2018 Nov 1;315(5):H1356-H1357.

2022

376. Smoum R, Grether U, Karsak M, Vernall AJ, Park F, Hillard CJ, **Pacher P**. Editorial: Therapeutic potential of the cannabinoid CB2 receptor. *Front Pharmacol*. 2022 Oct 7; 13:1039564. doi: 10.3389/fphar.2022.1039564. eCollection 2022.

LETTERS TO THE EDITOR

377. Ungvari ZI, Yabluchanskiy A, Hasko G, **Pacher P**. Age-dependent cardiovascular effects of sepsis in a murine model of cecal ligation and puncture: implications for the design of interventional studies. *Am J Physiol Heart Circ Physiol*. 2018 Aug 3. doi: 10.1152/ajpheart.00528.2018.
378. Z Ungvari, **P PACHER**. Simvastatin Promotes Angiogenesis - and Tumor Growth? *J Clin Inv* Letter 2002
379. **P PACHER**, Z Ungvari. Use of selective serotonin reuptake inhibitors and myocardial infarction. Correspondence letter. *Circulation* 2002;105,84.
380. Z Ungvari, **P PACHER**, A Csiszar. Simvastatin may induce angiogenesis and promote tumor growth

Pal Pacher M.D., Ph.D. - CV

similar to VEGF? In press: *Medical Hypotheses* 2002; 58(1):85-86.

PROCEEDINGS, OTHERS

381. **P PACHER**, Z Ungvári, V Kecskeméti, AZ Rónai. Electrophysiological changes in rat left atria and right ventricular muscle at different stages (2-18 weeks) of experimental diabetes. *Proceedings of 13th World Congress of Cardiology* 1998; 217-220.
382. V Kecskeméti, P PACHER, K Tekes, J Timár, S Gyarmati. Altered sensitivity of diabetic rat hearts to electrophysiologic actions of D-sotalol and prazosin. *Proceedings of 13th World Congress of Cardiology* 1998; 213-216.
383. V. Kecskemeti, P. PACHER, Zs. Bagi, K. Tekes and M.Zs. Koltai. Altered Myocardial Sensitivity to Drugs in Animals with Experimental Diabetes. *Proceedings of the 22nd European Section Meeting of the International Society for Heart Research* 2002, Szeged, Hungary
384. P PACHER, L Liaudet, JG Mabley, C Szabo. A novel ultrapotent PARP inhibitor improves cardiac and endothelial dysfunction in rat model of chronic heart failure. *Proceedings of the 5th International Congress on Coronary Artery Disease* 2003, Florence (Italy), p35-39.
385. Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. Pál Pacher. Interviewed by Helene F. Rosenberg. *J Leukoc Biol.* 2007 Dec;82(6):1390-2.

BOOK CHAPTERS

386. **P PACHER**, S Batkai and G Kunos. Cannabinoids. *Cardiovascular Pharmacology. In: Handbook of Experimental Pharmacology.* Springer 2005 pp. 599-627.
387. **P PACHER & C Szabó.** PARP activation and nitrosative stress in the development of cardiovascular disease in diabetes. In: *Diabetes and Cardiovascular Disease, second edition* (Ed: A. Veves), in Contemporary Cardiology Series, Humana Press 2005 pp. 167-191.
388. **P PACHER**, C Szabo. Peroxynitrite and Nitrosative Stress in Heart Failure- Role of MMPS, ADP-Ribose and PARP. In *Oxidative Stress: Clinical and Biomedical Implications* Editor Bashir M. Matata, 2007.
389. **P PACHER** and G Kunos. The endocannabinoid system and cardiovascular disease. In *Abdominal Obesity and the Endocannabinoid System: From Basic Clinical Management of Related Cardiometabolic Risk* Eds. Jean-Pierre Despres and Vincenzo Di Marzo. In press 2008
390. G Kunos and **P PACHER.** Endocannabinoids. *Hypertension Primer 4th Edition*, 2008.
391. **P PACHER** and G Kunos. Some potential Therapeutic Targets for Phytocannabinoids. *Cardiovascular, metabolic, liver, kidney, and inflammatory disorders.* In *Handbook of Cannabis*, 2014 Oxford University Press. Eds. Les Iversen and Roger G. Pertwee
392. VZ Varga, **P Pacher.** Cardiotoxicity of Drugs: Role of Mitochondria p93-110 in Mitochondrial Dysfunction by Drug and Environmental Toxicants, Volume I, First Edition. Edited by Yvonne Will and James A. Dykens. © 2018 John Wiley & Sons, Inc. Published 2018 by John Wiley & Sons, Inc

INTERVIEWS

Interviews, commentaries appeared in *Washington Post*, *Verge*, *Newsweek*, *Nature Medicine*, and other mainstream popular media.

Conference abstracts (over 500, not listed)